{"title": "PDF", "author": "PDF", "url": "https://www.sahpra.org.za/wp-content/uploads/2021/06/Consolidated-schedules_25-May-2021.docx.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 DEPARTMENT OF HEALTH MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) CONSOLIDATED SCHEDULES 25 MAY 2021 The Minister of Heal th has, in terms of section 22A (2) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), on the recommendation of the South African Health Products Regulatory Authority ( SAHPRA ), made and update d the Schedules in the Schedule . SCHEDULE In these Schedules, \"the Act\" means the Medicines and Related Substances Act, 1965 (Act 101 of 1965) Note : Where an alternative schedule(s) is included in natural parentheses at any point of an inscription, this is provided to indicate one or more alternative scheduling designation/s. Thi s is for information only and shall not be used in the interpretation of such inscription. SCHEDULE 0 a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, and which are intended to be ingested by man or animals as a food or applied to the body as a cosmetic, and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972) or that are registered in terms of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947); and (ii) analytical laboratory purposes . b. This Schedule shall include all substances or mixtures of such substances containing or purporting to contain substances referred to, including the salts and esters of such substances, where the existence of such salts and esters is possible, except whe re such substances or mixtures of substances are expressly excluded. This Schedule includes all substances or mixtures of substances subject to registration in terms of the Act and which are not listed in any of the other Schedules. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 2 SCHEDULE 1 a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and (ii) analytical laboratory purposes. b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and include s the following: (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded. c. In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice a nd subject to the indication for use of such substances and medicines and to the conditions determined by the Authority , to patients under his/her care, the Schedule 1 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner) Annexure 1C: Basic Ambulance Assistant Annexure 1D: Ambulance Emergency Assistant Annexure 1E: Emergency Care Technician Annexure 1F: Emergency Care Assistant (ii) Annexure 2: Dental Therapist (iii) Annexure 3: Optometrist (iv) Annexure 4: Podiatrist Acetanilide and alkyl acetanilides. Acetarsol, when intended for human vaginal use. Acetylcysteine, a. when used as a mucolytic in acute respiratory conditions for a maximum treatment period of 14 days; b. except when intended for injection or for the management of paracetamol overdosage. (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 3 Acyclovir, when intended for application to the lips in the early treatment of recurrent herpes simplex virus Anethole trithione. for application to skin. (S4) Antimony potassium tartrate and antimony sodium tartrate; in concentrations of 1 percent or more. (S0) Any compound structurally derived from either beta -aminopropylbenzene or beta -aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closu re); and presented as: a. preparations and mixtures when used as vasoconstrictors and decongestants in antihistamine -containing nose and eye preparations; and b. appliances for inhalation in which the substance is adsorbed onto solid material but excluding cath oral dosage forms in concentrations equivalent to 0,01 percent or less of arsenic trioxide; (S2) b. except when intended for injection. (S4) Ascorbic Acid -see Vitamin C. Azelaic acid. Bacitracin, when intended for topical application to the epidermis, nares and external ear. (S4) Bee venom, preparations intended for application to the skin. (S4) Belladonna alkaloids, when specifically intended for topical application. (S2) Benzethonium chloride, when intended for human vaginal use. Benzocaine, a. when inte nded for topical use; b. in oral preparations containing 2 percent or less of benzocaine; c. in lozenges containing 30 milligrams or less of benzocaine, per dosage unit; d. except when intended for ophthalmic or parenteral use. (S4) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 4 Benzydamine, a. preparations and mixtures containing intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day. (S3) b. except preparations and mixtures containing 3 p ercent or less of benzydamine, when intended for application to the skin (S0); or c. except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of b enzydamine per day and the pack size does not exceed 16 lozenges. (S0) d. except when indicated for human vaginal use. (S2) Bifidobacterium adolescentis, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparation s and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the fu nction ing preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu pe r dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioni ng pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a re gular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Bifidobacterium bifidum, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 5 \"When ingested on regular basis, probiotics should improve or normalise the microbial balance in t he human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Bifidobacterium breve, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Bifidobacterium lactis, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Bifidobacterium a nd mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Bifidobacterium longum subsp . preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby imp rove the function ing of the digestive tract/gut\". (S0) Bifonazole, when intended for application to the skin. (S4) Bioallethrin. Bitolterol. Boron, in oral preparations or mixtures containing more than 3 mg of Boron per recommended daily dose alone or in c ombination with other active pharmaceutical ingredients. (S0) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 6 Bufexamac, when intended for application to the skin. (S3) Bunamidine. Butoconazole, a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S4) or b. when intended for application to the skin. (S4) Calcium, a. in oral preparations or mixtures containing more than 1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection; (S3) c. except when indicated for the treatment of hyperphosphataemia; (S4) d. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Carbamoyl benzamide phenyl isoxazoline, except when intended and registered as a stock remedy in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Chlorhexidine, when intended for h uman vaginal use. (S0) Chloroform, prep arations and mixtures containing more than 0,5 percent and less than 20 percent of chloroform. (S0, S5) Chromium, in oral preparations or mixtures containing more than 200 \u00b5g of Chromium per recommended daily dose a lone or in combination with other active pharmaceutical ingredients. (S0) Ciclopirox . Clotrimazole, a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S4) and b. when intended for application to the skin. (S4) Collagenase clotridiopeptidase, when intended for application to the skin. Copper, a. in oral preparations or mixtures containing more than 4 mg of Copper per recommended daily dose alone or in combination with othe r active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 7 Cyanocobalamin -see Vitamin B12. Deanol and its derivatives, unless listed in another Schedule, when specifically packaged, labelled and used for industrial purpos es including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are intended to be ingested by man or animals as food or applied to the body as a cosmetic and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972, (Act 54 of 1972)and for analytical laboratory purposes. (S5) Diclofenac, a. when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S3) b. except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0) c. except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2) d. except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days. ( S2) e. except when intended for veterinary use. (S3) Diosmine. Dithiazanine. Econazole, a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S4) or b. when intended for application to the skin. (S4) Enilconazole, when inte nded for application to the skin. (S4) Ephedra alkaloids (natural or synthetic), a. when intended for application to skin, eyes, ears and nares and containing 1 percent or less of ephedra alkaloids, and not intended for export; (S6) b. except oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, su bject to a maximum pack size of 360 milligrams and limited to one pack per customer. (S2) Ephedrine, a. preparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1 percent or less of ephedrine, and not intended for export; (S6) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 8 b. except products registered in terms of the Act, not intended for export, and being oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, contain ing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer. (S2) Escin (aescin); medicinal preparations and mixtures t hereof intended for application to the skin and containing 1 percent or less of escin. (S3) Ether (diethyl ether); in concentrations percent. (S5) Ethyl chloride. Ethylphenylephrine. Etofenamate, when intended for application to the skin. ( S3) Felbinac, when intended for application to the skin. (S3) Fenbendazole, except when registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Fenticonaz ole, when intended for application to the skin. (S3) Fexofenadine. Flubendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Flufenamic acid, when intended for application to the skin. (S3) Fluorescein, when intended for ophthalmic use by the topical route only . (S3) Fluorides, a. in oral medicinal preparations or mixtures intended for ingestion containing not more than 0,25 milligrams of fluorine per dosage unit; b. except in toothpaste containing not more than than 0,15 percent fluoride; (S0) and c. except in mouth rinses containing not more than than 0,15 percent fluoride; (S0) d. except in oral medicinal preparations or mixtu res intended for ingestion containing more than 0,25 milligrams of fluorine per dosage unit. (S4) Flurbiprofen, a. when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 9 b. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation , provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0) c. except when intended for the treatment of post -traumatic conditions, for a maximum period of 5 days; (S2) d. except when intended for ophthalmic use. (S4) Folic Acid , in oral preparations or mixtures containing more than 500 \u00b5g of Folic Acid per recommended daily dose alone or in combination with other active pharmaceutical ingre dients. (S0) Glycosaminoglycan polysulphate (previously mucopolysaccharide poly -sulphuric intended for application to the skin. (S4) Gramicidin, when intended for topical application to the epidermis, nares and external ear. (S4) O-(-hydroxyethyl) rutosides. Hyaluronic acid and its salts, a. when intended for topical application to the skin; b. except when intended for use with contact lens solutions or as an ophthalmic lubricant in concentrations of not more than 0,1 perce nt; (S0) c. except when intended for ophthalmic use in preparations (except injectables) containing more than 0,1 percent; (S2) d. except when intended for parenteral use; (S4) e. except in preparations containing less than 2,5 percent when intended for topical use in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972), 5-Hydroxy Tryptophan, a. in oral preparations with a maximum daily dose not exceeding 220 mg of 5 -Hydroxy tryptophan, alone or in combinatio n with other active pharmaceutical ingredients; (S5) b. except in oral preparation with a maximum daily dose not exceeding 220 mg of 5 -Hydroxy alone or in combination with other active pharmaceutical ingredients, with general health claims as a health supple ment . (S0) Hyoscine butylbromide; substances, preparations and mixtures thereof - a. when intended for oral administration in pack sizes not exceeding 20 tablets of 10 mg strength or less, or 100 ml of oral liquid dosage of 0.1% mass/ volume or less; (S2) b. except transdermal preparations when intended for the prevention of the symptoms of motion sickness; (S2) c. except when intended for parenteral administration. (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 10 Icodextrin. Ibuprofen a. when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen, and presented in a pack size exceeding 50 grams; (S0) b. when contained in oral medicinal preparations, intended for human use only, supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post -traumatic conditions in adults and children ov er 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exce ed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight. (S2, S3). c. except when intended for veterinary use . (S3) Idoxuridine, when intended for application to the skin. (S4) Indanazoline. Indometacin, a. when intended for application to the skin; (S3) b. except when intended for the emergency treatment of acute gout attacks; (S2) c. except when intended for veterinary use. (S3) Iodine, a. in oral preparations or mixtures containing more than 150 \u00b5g of Iodine per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Iron, a. in oral preparations or mixtures containing more than 24 mg of Iron per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection; (S3) c. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultur al Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Irrigation fluids, being sterile fluids intended for irrigation of wounds or hollow visci. Isoconazole, when intended for a. human vaginal use specifically for the treatment of recurrent vaginal cand idiasis (S4); and DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 11 b. application to the skin. (S4) Ketoconazole, when intended for a. application to the skin, b. except preparations and mixtures containing not more than 1,0 percent of ketoconazole, when intended for the prevention and treatment of dandruff. (S0 , S4) Ketoprofen , a. when intended for application to the skin; (S3) b. except when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhoea), minor aches and pains associated with the common cold and fever, at a maximum dose of 75 milligrams of ketoprofen in 24 hours; (S2) c. except when intended for the emergency treatment of acute gout attacks; (S2) d. except when intended for the treatment of post -traumatic conditions, subject to a maximum dose of 100 milligrams of ketoprofen per day, for a maximum treatment period of 5 days; (S2) e. except in the form of lozenges indicated and intended for the relief of pain as sociated with sore throats in patients 18 years and older subject to - (i) a maximum of 12,5 milligrams per lozenge; (ii) a maximum of 5 lozenges in any 24 hour period; (iii) a maximum treatment period of 3 days; and (iv) a maximum pack size of 15 lozenges. (S2) Lactobacillus acidophilus, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the dig estive tract/gut\". (S0) Lactobacillus brevis, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 12 \"When ingested on regular basis, probiotics should improve or normalise the microbial balance in the human i ntestines and thereby improve the functioning of the digestive tract/gut\" . (S0) Lactobacillus caucasicus, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains contai ning 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract/gut\" . (S0) Lactobacillus casei, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a r egular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioni ng of the digestive tract/gut\". (S0) Lactobacillus fermentum, a. in pharmaceutical preparations and mixtures with medicinal cla im(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract/gut\" . (S0) Lactobacillus gasseri, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains co ntaining 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Lactobacillus helveticus, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingest ed on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract/gut\" . (S0) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 13 Lactobacillus johnsonii, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial ba lance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Lactococcus lactis, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive trac t/gut\" . (S0) Lactobacillus paracasei, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioni ng of the digestive tract/gut\". (S0) Lactobacillus plantarum, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbi al balance in the human intestines and thereby improve the functioning of the digestive tract/gut\" . (S0) Lactobacillus reuteri, a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digest ive tract/gut\" . (S0) Lactobacillus rhamnosus, DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 14 a. in pharmaceutical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract/g ut\". (S0) Lactobacillus salivarius, a. in pharmaceut ical preparations and mixtures with medicinal claim(s); b. except in pharmaceutical preparations and mixtures for one or more strains containing 1 x 109 cfu per dosage unit with the general health claim: \"When ingested on a regular basis, probiotics should i mprove or normalise the microbial balance in the human intestines and thereby improve the function ing of the digestive tract/gut\". (S0) Lidocaine, a. when intended for topical use; b. in oral preparations containing 2 percent or less of lidocaine, per dosage unit; c. except when intended for ophthalmic or parenteral use; (S4) d. except when intended for the treatment of neuropathic pain associated with previous herpes zoster infection. (S4) Lignocaine - see Lidocaine. Local anaesthe tics, except a. when intended for ophthalmic or parental use; (S4) b. oxybuprocaine, proxymetacaine and tetracaine, when contained in eye drops intended for emergency treatment of \"arc eyes\"; (S2) and c. ophthalmic preparations registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Loratidine . Lufenuron, except when intended and registered as a systemic preparation agains t fleas in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Luxabendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Far m Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Lysozyme, when intended for application to the skin. (S4) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 15 Magnesium, in oral preparations or mixtures containing more than 250 mg of Magnesium per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Malathion, except when intended and registered as an ectoparasiticide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 o f 1947). Manganese, a. in oral preparations or mixtures containing more than 4 mg of Manganese per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. in preparations thereof for injection when intended for veteri nary use. Mebendazole, except when registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Methenamine (hexamine), when intended for application to the sk in, (S4) Methionine, a. in oral preparations containing more than the maximum daily dose of 210 mg of methionine alone or in combination with other active pharmaceutical ingredients. ( S0) . Miconazole, a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S4) and b. when intended for application to the skin. (S4) c. except for topical treatment of fungal infections of the mouth. (S2) Microfibrillar collagen hydrochloride. Molybdenum and derivatives thereof in oral preparations or mixtures containing more than 230 \u00b5g of Molybdenum per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Morantel except when registered as an anthelmintic in terms of the provisions of the Fe rtilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). N-acetyl -aspartyl -glutamic acid. Naphazoline, when intended for nasal use. (S2) Naproxen a. when contained in preparations intended for application to the skin; (S2, S 3) b. when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origi n at a maximum dose of 600 milligrams naproxen base (660 DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 16 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the stated maximum treatme nt period; (S2, S3) c. except when intended for veterinary use. (S3) Niacin (Nicotinic Acid, Vitamin B3) and derivatives thereof, a. in oral preparations or mixtures containing more than 35 mg of Niacin per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except when intended for hypercholesterolaemia and for the management of dyslipidaemias. (S4) Nicotinamide and derivatives thereof, in oral preparations or mixtures containing more than 500 mg of Nicotinamide p er recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Nicotine, a. when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for contin uous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; b. except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4 mg nicotin e per piece; (S0) c. except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2) d. except when intended for human medicinal use as an aid to smo king cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21 mg/ 24 hours or 25 mg/ 16 hours; (S2) e. except when registered as metered sprays containing not more t han 1 mg per dose; (S2) f. except when registered as oral solid dosage forms containing not more than 2 mg; (S2) g. except when registered as inhalers containing not more than 10 mg per cartridge; (S2) h. except when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended). (S3) Nitrofurantoin, when intended for application to the skin. (S4) Nitrofurazone, when intended for application to the skin. (S4) Normal Saline (Sodium chloride 0,9 percent m/v) when intended for injection, in a dosage form not exceeding 20 millilitres in volume. (S0, S3) Nystatin, DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 17 a. when intended for application to the skin, and b. when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis, and c. except when presented as oral drops containing not more than 100 000 I.U. per millilitre , (S2) d. except when intended for systemic use or the initial treatment of vaginal candidiasis , (S4) e. except when intended and registered as a stock remedy for pigeons in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Ornidazole, when intended for application to the skin. (S4) Orthodichlorobenzene, when intended for topical human medicinal use. Oxetacaine (Oxethazaine), a. in oral preparations containing an antacid; b. except when intended for ophthalmic or parenteral use. (S4) Oxibendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Oxymetazoline, when intended for nasal use. (S2) Pancreatin. Pantothenic Acid -see Vitamin B5. Paracetamol, except - a. immediate release tablets or capsules each containing 500 milligrams or less of paracetamol, or in individually wrapped powders or in sachets containing 1 000 milligrams or less of paracetamol, subject to - (i) a maximum of 12,5 grams of paracetamol per pr imary pack, and (ii) in the case of tablets or capsules, presented in blister strip packaging or in containers with child-resistant closures; and (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): \"CONTAINS PARACETAMOL - READ THE PACKAGE INSERT\"; (S0) b. in liquid or syrup dosage form containing 120 millig rams or less of paracetamol per 5 millilitres or in paediatric drops containing 120 milligrams or less of paracetamol per 1,2 millilitres, subject to - (i) a maximum of 100 millilitres per primary pack in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres; (ii) a maximum of 20 millilitres per primary pack in the case of the paediatric drops; DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 18 (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate containe r label and outer label (carton): \"CONTAINS PARACETAMOL - READ THE PACKAGE INSERT\"; (S0) c. when contained in rectal suppositories. (S2) d. when contained in modified release formulations. (S2) e. when intended for injection. (S3) Paradichlorobenzene, when intende d for topical human medicinal use. Penciclovir, when intended for application to the lips in the early treatment of recurrent herpes simplex virus infections. (S4) Pentosan polysulfate sodium, except when for the treatment of interstitial cystitis . (S3) Phenylephrine, except ophthalmic preparations containing 0,2 percent or less. (S0) Phospholipids, when applied for therapeutic purposes. Phosphorus, in oral preparations or mixtures containing more than 250 mg of Phosphorus per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Polymixin B, when intended for topical application to the epidermis, nares or external ear. (S4) Pramoxine. Prilocaine, a. in topical preparations containing 10 percent or less o f prilocaine; b. except when intended for ophthalmic or parenteral use. (S4) Procaine, when intended for oral administration. Propentofylline, when intended for veterinary use. (S4) Propylhexedrine, when used as a vasoconstrictor arations and inhalants. (S4) Proteolytic (fibrinolytic) enzymes, a. for oral use and b. when intended for application to the skin, and c. except when intended for soft contact lens cleaners; (S0) and d. except when intended for injection. (S4) Pyrantel pamoate, inc luding veterinary use, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Correct DocuSign Envelope ID: Vitamin B2. Selenium, a. in oral preparations or mixtures containing more than 200 \u00b5g of Selenium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection when intended for veterinary use. (S4) Sertaconazole, when intended for application to the skin. (S4) p-Synephrine, a. oral preparations and mixtures registered in terms of the Act and intended for the symptomatic relief of nasal and si nus congestion, where the recommended daily dose for adults is 50 milligrams or less and for children 6 to 12 years is 25 milligrams or less, with a maximum pack size of 5 days; (S6) b. except preparations and mixtures registered in terms of the Act and inten ded for application to the skin, ears and nares containing 1 percent or less of p -synephrine and containing 0,2 percent or less for application to the eyes; (S0) c. except oral preparations and mixtures registered in terms of the Act and intended for the symp tomatic relief of nasal and sinus congestion, where the recommended daily dose for adults is more than 50 milligrams and for children 6 to 12 years is more than 25 milligrams. (S2) Terbinafine, when intended for application to the skin. (S4) Tetracaine, a. when intended for topical use; b. in oral preparations containing 2 percent or less of tetracaine, per dosage unit; c. except when contained in eye drops intended for the emergency treatment of \"arc eyes\"; (S2) d. except when intended for ophthalmic or (S4) Tetrahydrozoline, when intended for nasal use. (S2) Thiabendazole, when intended for application to the skin. (S4) Thiamine -see Vitamin B1. Thiomersal. Thiram, except when intended and registered as a fungicide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 20 Ticlatone, when intended for application to the skin. Tioconazole, a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candid iasis; and b. when intended for application to the skin. (S4) Tolmetin, when intended for application to the skin. (S3) L-Tryptophan, a. in oral preparations with a maximum daily dose not exceeding 220 mg of L -tryptophan, alone or in combination with other active pharmaceutical ingredients; (S5) b. except in oral preparation with a maximum daily dose not exceeding 220 mg of L -tryptophan alone or in combination with other active pharmaceutical ingredients, with general health claims as a health supplement . (S0) Tyrothricin when intended for topical application to the epidermis, nares and external ear. (S4) Vanadium, a. in oral preparations or mixtures containing more than 182 \u00b5g of Vanadium per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0) Vitamin B1 (Thiamine) and derivatives thereof, a. in oral preparations or mixtures con taining more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) Vitamin B2 (Riboflavin) and derivatives thereof, a. in oral prepar ations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) Vitamin B5 (Pantothenic Acid) and derivati ves thereof, a. in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) Vitamin B6 (Pyr idoxine) and derivatives thereof, a. in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 21 Vitamin B12 (Cyanocobalamin) and derivatives thereof, a. in oral preparations or mixtures containing more than 100 \u00b5g of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) Vitamin C (Ascorbic Acid), a. in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in preparations thereof for injection. (S3) Vitamin H (Biotin) and derivatives thereof, in oral preparations or mixtures containing more than 500 \u00b5g of Vitamin H per recommended daily dose alone or in combination with other active pharmaceutical ingredient s. (S0) Vitamin K and derivatives thereof, a. in oral preparations or mixtures containing more than 120 \u00b5g of Vitamin K per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0) b. except in injection preparations; (S3 ) c. except when used in infant milk feeds or formulae in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972). Water for Injection in a dosage form not exceeding 20 milliliters in volume. (S3) Xylometazoline, when intended for nasal use. (S2) Zinc and derivatives thereof, a. in injection preparations when intended for veterinary use; (S3) b. except in oral preparations or mixtures containing not more than 25 mg of Zinc per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0 ,) c. except when intended for topical use; (S0) d. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 22 ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduates only) registered with Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates only) LOCAL ANAESTHETIC Substance : Lignocaine h ydrochloride Indication : Local Anaesthetic Route of Administration : Topical application WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) LOCAL ANAESTHETIC Substance : Lignocaine h ydrochloride Indication : Local Anaesthetic Route of Administration : Topical application WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 23 ANNEXURE 1C: BASIC AMBULANCE ASSISTANT BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 24 ANNEXURE 1F: EMERGENCY CARE ASSISTANT EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 25 ANNEXURE 2: DENTAL THERAPIST DENTAL THERAPIST (Bachelors degree in Dental Therapy) registered with Health Professions Council of South Africa DENTAL THERAPIST (Bachelors degree in Dental Therapy ) ANALGESIC, ANTIPYRETIC, ANTI INFLAMMATORY Substance : Paracetamol Indication : Dental pain Route of Administration : Oral SURFACE ANAESTHETIC Substance : Lidocaine / Lignocaine h ydrochloride Indication : Dental surface anaesthesia Route of Administration : Topical ANTI -VIRAL Substance : Acyclovir Indication : Viral infection of lips Route of Administration : Topical VITAMINS AND MINERALS Substance : - Indication : Applicable to Dentistry Route of Administration : Oral MOUTH AND THROAT PREPARATIONS Substance : - Indication : Applicable to Dentistry Route of Administration : Oral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 26 ANNEXURE degree in Optometry - B OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber. OPTOMETRIST OPHTHALMIC PREPARATIONS: OTHER Substance : Fluorescein Indication : For diagnostic purpose only i.e. In detecting corneal abrasions and foreign bodies inthe eye, in applanation tonometry, in assessing the patency of the nasolacrimal duct and in contact lens fittingprocedures Route of Administration : Intra-ocular ANALGESIC Substance : Paracetamol Indication : Mild Pain Route of Administration : Oral ANALGESIC/ ANTI INFLAMMATORY Substance : Ibuprofen Indication : Mild to Moderate Pain Route of Administration : Oral SYMPATHOMIMETIC Substance : Phenylephrine Indication : Minor ocular irritation Route of Administration : Topical (Drops) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 1 27 ANNEXURE 4: PODIATRIST ANNEXURE 4: PODIATRIST PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) PODIATRIST LOCAL ANAESTHETIC Substance : Amethocaine/ Tetracaine Indication : Local Anaesthesia Route of Administration : Topical (Cream) LOCAL ANAESTHETIC Substance : Chloroethane (Ethyl Chloride) Indication : Local Anaesthesia Route of Administration : Topical (Spray) LOCAL ANAESTHETIC Substance : Lignocaine/ Lidocaine Indication : Local Anaesthesia Route of Administration : Topical (Pump, Spray, Cream, Patch) - END SCHEDULE 1 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 28 SCHEDULE 2 (i) All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal p urpose; and (ii) analytical laboratory purposes. (ii) All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and include s the following: (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded. (iii) In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within their scope of practice and subject to the indication for use of su ch substances and medicines and to the conditions determined by the Authority , to patients under his/her care, the Schedule 2 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner) Annexure 1C: Basic Ambulance Assistant Annexure 1D: Ambulance Emergency Assistant Annexure 1E: Emergency Care Technician Annexure 1F: Emergency Ca re Assistant (ii) Annexure 2: Dental Therapist (iii) Annexure 3: Optometrist (iv) Annexure 4: Podiatrist Aconite alkaloids, 0,02 percent or more. (S0) Acrivastine. Adrenaline (epinephrine), except - a. ophthalmic preparations when intended for glaucoma, and b. preparations for injection. (S3, S4) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 poisonous and glycosides, and the salts of such poisonous alkaloids and glycosides, when not specifically nam ed in any other Schedule. Amethocaine - see b. when listed separately in these Schedules. (S5) Antimicrobial substances, namely a. griseofulvin, mupirocin, natamycin when intended for application to the skin, nares and external ear; (S4) b. nystatin preparations intended for application to the oral cavity, nares and external ear. (S1, S4) Apomorphine; except when indicated for the treat ment of erectile dysfunction. (S4) Aptocaine. Arecoline. Arsenic; a. except in oral dosage forms containing the equivalent of 0,01 percent or less of arsenic trioxide; (S1) b. except when intended for injection. (S4) Aspirin (acetyl salicylic acid), when inten ded for: a. the treatment of children or adolescents; and b. the prophylaxis of cardiovascular disease in adults (S0) Atovaquone, a. when co -formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S4) Atropine, except a. when intended for use in ophthalmic preparations; (S3) b. when intended for use in injections. when intended fo r nasal administration as an aqueous spray, other than by pressurised aerosol, and indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to a. a maximum dose of 100 micrograms per nostril and a maximum daily dose of 200 micrograms of per nostril and b. a maximum pack size of 200 doses. (S3, S4) Belladonna alkaloids, except when intended for topical application. (S1) Benproperine. Benzydamine, a. when intended for use human vaginal use; (S3) b. except preparations and mixtures containing 3 percent or less of benzydamine, when intended for application to the skin; (S0) c. except preparations and mixtures intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day; (S1) d. except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not e xceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0) Bevonium methylsulphate. Bismuth, when intended for oral use. Bromides, preparations containing less than 80 milligrams of bromine recommended da Budesonide, DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 31 a. when intended for the prophylaxis and treatment of seasonal and perennial allergic rhinitis in adults and children aged 12 years and older; (S3) b. except when intended for inhalation and nasal administration, unless listed in another Schedule. when contained in respirator solutions; (S3) and b. when intended for injection. (S4) Carisoprodol. Cetirizine. Chlormezanone; preparations containing not more than 100 milligrams per recommended dose. (S5) Chlorodyne (as described by Chloroform and Morphine Tincture BP 1980); preparations containing 5,0 percent or less of chlorodyne in combination with other active medicinal ingredients. (S6) Chlorpheniramine. Chlorprenaline. Cholestyramine. Chlorzoxazone. Cimetidine, when intended for the short -term symptomatic relief of heartburn, dyspepsia and hyperacidity, subject to a maximum unit dose of 200 milligrams, a maximum daily dose of 800 milligrams and a maximum treatment period of 2 weeks. Clemastine. the [treatment] prevention of migraine. (S3) Codeine (methylmorphine), a. oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as bas e) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres, when contained in products registered in terms of the Act, and not intended for export; c. excep t oral solid preparations, in combination with one or more therapeu tically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit; ( S3) d. except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit; (S3) e. except single component codeine preparations. (S6) Colchicine, when intended for the emergency treatment of acute gout, subject to a maximum total treatment course of 6 milligrams. (S3) Cyclandelate. Cyclizine. Cyclopentolate, except when intended for ophthalmic administration. (S3) Cyproheptadine, when indicated for use. (S5) Desloratidine. Dexchlorpheniramine. Dextromethorphan. Diclofenac, a. when intended for the emergency treatment of acute gout attacks, subject to a maximum da ily dose of 150 mg for a maximum treatment period of 3 days; (S3) b. when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days; c. except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 33 d. except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1) e. except whe n intended for veterinary use. (S3) Dicyclomine. Diphenoxin (or diphenoxylic acid), mixtures containing, per dosage unit, 0,5 milligrams or less of difenoxin, calculated as the base, and a quantity of atropine sulphate equal to at least 5 percent of such quantity of difenoxin, calculated as the base, as is present in the mixture. (S6) Diphenoxylate preparations containing not more than 2,5 milligrams of diphenoxylate, calculated as the base, and not less than 25 micrograms of atropine sulphate per dosage u nit. (S6) Dihydrocodeine, a. oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of dihydrocodeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, when contained in products registered in terms of the Act, and not intended for export; b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of dihydrocodeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millili tres, when contained in products registered in terms of the Act, and not intended for export; c. except oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of dihydrocodeine (calculated as base) per dosage unit; (S3) d. except liquid oral preparations and mixtures, in combination wit h one or more therapeutically active substances, containing more than 10 milligrams of dihydrocodeine (calculated as base) per 5 millilitre dosage unit; (S3) e. except Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 34 a. when intended and labelled for the chemoprophylaxis of malaria in those aged 8 years and older . (S4) Doxylamine. Ebastine. Emedastine. Emepronium. Emetine, substances, percent of alkaloids, calculated as emetine. (S4) Ephedra alkaloids (natural or synthetic), contained in products registered in terms of the Act, and not intend ed for export, unless listed separately in the Schedules, a. oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ep hedra alkaloids per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S6) b. except when intended for application to skin, eyes, ears and nares and containing 1 percent or less of ephedra alkaloids. (S1) Ephedrine, contained in products registered in terms of the Act, and not intended for export, a. oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S6) b. except p reparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1 percent or less of ephedrine. (S1) Epinastine. Ergot alkaloids (natural or synthetic), the treatment of migraine. (S4) Ergotamine. Estradiol, a. when intended for human vaginal use; b. except when intended for oral contraception; (S3) c. except when intended for hormone replacement therapy. (S4) Ethylmorphine: a. oral solid preparations, in combination with one or more therapeutically active su bstances, and containing 20 milligrams or less of ethylmorphine (calculated as base) per dosage unit; (S6) and DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 35 b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, and containing 20 milligrams or less o f ethylmorp hine (calculated as base) per 5 milliliter dosage unit. (S6) Etilefrine. Etodroxizine, preparations and mixtures when used solely as an antihistamine. (S5) Exalamide. Famotidine, when intended for the short -term symptomatic relief of heartburn caused by excess acid, subject to - a. a maximum dose of 10 milligrams; b. a maximum daily dose (per 24 hours) of 20 milligrams; c. a maximum treatment period of 2 weeks. (S4) Fedrilate. Fenoprofen, a. when intended for the emergency treatment of acute gout attacks, and b. when intended for the treatment of post -traumatic conditions, for a maximum treatment period of 5 days. (S3) Fenoterol, except a. when contained in respirator solutions; (S3) and b. when int ended for injection or for the prevention or delay of labour. (S4) Flavoxate. Flunarizine. Flunisolide, when intended for nasal administration as an aqueous spray, other than by pressurised aerosol, in a strength not exceeding 0,025 percent (m/v) , and indi cated for treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- a. a maximum dose of 50 micrograms per nostril and a maximum daily dose of 100 micrograms per nostril in the case of adults and children over 16 years of age; b. a maximum dose of 25 micrograms per nostril and a maximum daily dose of 75 micrograms in children 12 to 16 years of age; c. a maximum pack size of 240 doses. (S3, S4) Flurbiprofen, a. when intended for the treatment of post -traumatic conditions, for a maximum period of 5 days;(S3) b. except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 36 (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1) c. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation , provided that in the case of ap plication by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0) d. except when intended for ophthalmic use. (S4) Fluticasone furoate, a. when intended for nasal administration, as an aqueous spray, in the short -term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 55 micro grams per nostril; and (ii) a maximum pack size limit of 120 doses. (S3) b. except when intended for administration other than by inhalation or nasal administration. (S4) Fluticasone propionate, a. when intended for nasal administration, as an aqueous spray , in the short -term (less than 6 months) prophylaxis and treatment of symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 100 micrograms per nostril; (ii) and a maximum pack size limit of 12 0 doses. (S3) b. except when intended for administration other than by inhalation or nasal administration. (S4) Fusafungine. Fusidic acid, when intended topical application . (S4) Gadopentetic acid. Gamma benzene hexachloride when intended to be used for t he second line treatment of lice in a pack size not exceeding 60 millilitres . (S4) Gelsemium alkaloids. Griseofulvin, when intended for application the skin, nares and external ear. (S4) Halogenated hydroxyquinolines, when intended for application to t he skin. (S4) Haemophilus influenzae vaccine (Hib). Hepatitis B vaccine. Hexametazine. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 37 Hexoprenaline - a. except when contained in respirator solutions; (S3) and b. except when intended for injection or for the prevention or delay of labour. (S4) Homatropine; preparations and mixtures thereof, except ophthalmic preparations. (S3) Hormones (natural or synthetic, including recombinant forms), with either hormonal, prohormonal or anti - hormonal action unless listed elsewhere in the Schedules, a. when intended for huma n vaginal use, and b. when specifically intended for emergency postcoital contraception. (S3, S4, S5) Human pappillomavirus vaccine. Hyaluronic acid and its salts, a. when intended for ophthalmic use in preparations (except injectables) containing more than 0,1 percent; b. except when intended for use with contact lens solutions or as an ophthalmic lubricant in concentrations of not more than 0,1 percent; (S0) c. except when intended for topical application to the skin; (S1) d. except when intended for parenteral use; (S4) e. except in preparations containing less than 2,5 percent when intended for topical use in terms of the provisions of the Foodstuffs, Cos metics and Disinfectants Act, 1972 (Act 54 of 1972). Hydrocortisone and hydrocortisone acetate, when used in a. maximum concentration of 1 percent in preparations intended for application to the skin, and b. in a maximum concentration of 1 percent used in combin ation with miconazole for topical application in the treatment of athlete's foot. (S4) Hydroquinone; preparations and mixtures containing 2 percent or less thereof, when intended for application to the skin. (S3) Hyoscine butylbromide; substances, preparat ions and mixtures thereof - a. when intended for oral administration in pack sizes exceeding 20 tablets or 100 ml, or strengths exceeding 10 mg per oral solid dosage form or 0.1% mass/ volume; (S1) b. transdermal preparations when intended for the prevention of t he symptoms of motion sickness; (S3) c. except when intended for parenteral administration. (S3) Ibuprofen, a. when contained in oral medicinal preparations, intended for human use only in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 38 of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight. (S3) b. when contained in oral medicinal preparations, intended for human use onl y as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post-traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S1, S3) c. for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S3) d. except when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen; (S0, S1) e. except when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of p ost-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1) f. except when intended for the treatment of haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age; (S4) g. except when intended for veterinary use. (S3) Indometacin, a. when intended for the emergency treatme nt of acute gout attacks; (S3) b. except when intended for application to the skin ; (S1) c. except when intended for veterinary use. (S3) Influenza virus vaccine. Ipratropium, except when contained in respirator solutions. (S3) Isoaminile. Isoprenaline (isoproterenol), except a. when contained in respirator solutions; (S3) and b. when intended for injection. ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 39 Isopropamide. Isothipendyl. Ketoprofen , a. when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhoea), minor aches and pains associated with the common cold and fever, at a maximum dose of 75 milligrams of ketoprofen in 24 hours; b. when intended for the emergency tre atment of acute gout attacks or for the treatment of post -traumatic conditions, subject to a maximum dose of 100 milligrams of ketoprofen per day, for a maximum treatment period of 5 days; c. in the form of lozenges indicated and intended for the relief of p ain associated with sore throats in patients 18 years and older subject to - (i) a maximum of 12,5 milligrams per lozenge; (ii) a maximum of 5 lozenges in any 24 hour period; (iii) a maximum treatment period of 3 days; and (iv) a maximum pack size of 15 lozenges. (S3) d. except when intended for application to the skin. (S1) Ketotifen. Lansoprazole, when intended for the temporary short -term relief of heartburn and hyperacidity, subject to - a. maximum daily dose of 15 milligrams b. maximum treatment period of 14 days. (S4) Levocaba stine. Levocetirizine. Levodropropizine. Levonorgestrel, a. when intended for emergency post coital contraception; b. except when intended for oral contraception; (S3) c. except when administered via an Intra Uterine System. (S4) Lithium salts, when intended for application to the skin. (S5) Local anaesthetics, a. except when intended for ophthalmic and parental use; DocuSign b. oxybuprocaine, proxymetacaine and tetracaine, when contained in eye drops intended when intended for the treatment of post -traumatic conditions, for a maximum treatment period of 5 days; and b. preparations containing mefenamic acid as the only therapeutically acti ve substance, when intended for human use only in the treatment of primary dysmenorrhoea, subject to a maximum daily dose of 500 millligrams 3 times a day and a maximum treatment pe riod of 3 days; (S3) c. except when intended for veterinary use. (S3) Melatonin, when used for the treatment of desyncronosis (jet -lag) in doses not exceeding 6 milligrams daily. (S4). Mometasone furoate, when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to a. a maximum dose of 200 microgr ams per nostril in adults and 50 micrograms per nostril in children; and b. a maximum pack size of doses. S4) oxides, substances, preparations and mixtures thereof, containing less than 3 per cent of mercury. (S4) Mercury organic compounds a. substances, preparations and mixtures in the form of aerosols, intended for application to the skin and mucous membranes and substances, b. preparations and mixtures containing the equivalent of 0,6 percent or more of elemental mercury, intended for application to the skin and mucous membranes, c. except phe nylmercuric nitrate when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Mesna, except preparations intended for injection. (S4) Metaproterenol (orciprenaline), exce pt a. when contained in respirator solutions; (S3) and b. when intended for injection. (S4) c. when intended for the prevention or delay of labour, (S4) Methixene. Methocarbamol. Metholilazine. Methoxyphenamine. Metronidazole, when intended for human vaginal use, specifically for the treatment of recurrent bacterial vaginosis and except when intended and registered for use in pigeons in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). (S4) Miconazole, when intended for human use in preparations containing 2 percent or less of miconazole, for the topical treatment of fungal infections of the mouth (oral candidiasis). (S1, S4) Minoxidil, when intended for application to the scalp in preparati ons containing not more than 2 percent (m/v) and which are registered in terms of the Act. (S4) Mizolastine. Morphine; mixtures containing 0,2 percent as anhydrous morphine. (S6) Mumps vaccine. Mupirocin, when intended for a the skin, nares and external ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 Nabumetone, when intended for the treatment of post -traumatic conditions, for a maximum treatment period of 5 days. (S3) Naphazoline, except when intended for nasal use . (S1) Naproxen a. when intended for the treatment of acute gout attacks, for a maximum treatment period of 5 days in patients over 16 years of age; (S3) b. except when contained in preparations intended for application to the skin;(S1) and c. except when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origin at a maximum dose of 60 0 milligrams naproxen base (660 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the s tated maximum treatment peri od; (S1, S3) d. except when intended for veterinary use. (S3) Natamycin, when intended for application to the skin, nares and external ear. (S4) Nedocromil. Nicergoline. Nicotine, a. when registered for human medicinal use as an aid to smoking cessation and p resented as nicotine gum or lozenges containing more than 4mg nicotine per piece; b. when registered as metered sprays containing 1mg per dose or less; c. when registered as oral solid dosage forms containing 2mg or less; d. when registered as inhalers containing 10mg or less per cartridge; e. when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 2 4 hours or 25 mg/ 16 hours; f. except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4mg nicotine per piece; (S0) g. except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; (S1) h. except when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended). (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 43 Nizatidine, when administered orally for short -term symptomatic relief of heartburn and hyperacidity, subject to - a. a maximum dose of 150 milligrams; b. a maximum daily dose of 300 milligrams; c. a maximum treatment period of two weeks. (S4) {(+)-norpseudoephedrine - see cathine (S6)} Noscapine. Nux vomica; substances, preparations and mixtures thereof, except when register ed in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Nystatin, a. when presented as oral drops containing not more than100 000 I.U. per millilitre , and b. except when intended for app lication to the skin, (S1) and c. except when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis, (S1) and d. except when intended for systemic use or the initial t reatment of vaginal candidiasis, (S4) e. except when in tended and registered as a stock remedy for pigeons in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Octatropine. Oleoresin of aspidium (Filix Mas). Olopatidine . Omeprazole, when intended for the temporary, short -term relief of heartburn and hyperacidity, subject to: a. a maximum daily dose of 20 milligrams b. a maximum treatment period of 14 days. (S4) Opium; mixtures containing not more than 0,2 ca lculated as anhydrous morphine. (S6) Orlistat, when used in a dose not exceeding 60 milligrams per main meal and not exceeding a maximum dose of 180 milligrams per 24 -hour period. (S3) Orphenadrine, when contained in preparations intended for use as a musc le relaxant. (S4) Otilonium bromide. Oxatomide. Oxybuprocaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4) Oxymetazoline, except when intended for nasal Pantoprazole, when intende d for the temporary short -term relief of heartburn and hyperacidity, subject to: a. maximum daily dose of 20 milligrams b. maximum treatment period of 14 days. (S4) Papaverine; substances, preparations and mixtures thereof. Paracetamol, a. when contained in rectal suppositories, or b. when contained in modified release formulations. (S0, S1, S3) Pentoxyfylline. Perfluorooctane, except when intended contained in products registered in terms of the Act, and not intended for export, unless listed separately in the Schedules, a. oral preparations and mixtures where the recommended daily dose fo r adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a ma ximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S6) Phenyltoloxamine. Pholcodine, when prepared, mixed or compounded - a. containing 20 milligrams or less of pholcodine (calculated as base) per d osage unit ; or b. containing 20 milligrams or less of pholcodine (calculated as base) per 5 millilitre dosage unit in the case of oral liquid preparatiosn and mixtures . (S6) Pholedrine. Pimethixene, preparations and mixtures thereof when as an antihistaminic. (S5) when contained in respirator solutions. (S3) Piroxicam, a. when intended for the emergency treatment of acute gout attacks, and b. when intended for the treatment of post -traumatic con ditions, for a maximum treatment period of 5 days. (S3) Pizotifen; preparations and mixtures, when intended for prophylaxis of migraine. (S5) Pneumococcal vaccine, conjugated. Podophyllum resin; preparations percent or less the reof. (S4) Poldine methylsulphate. Polio vaccine. Potassium, a. in oral preparations or mixtures containing more than 20 millimoles (1500mg) of potassium per 24 hours; b. except when intended for intravenous infusion or for injection; (S3) and c. except when contained in oral rehydration preparations. (S0) Povidone iodine when intended for application to the vagina. (S0) Prifinium bromide. Procaterol, except when contained Procyclidine. Proguanil, a. when co -formulated with at ovaquone and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S4) Proglumide. Promethazine, a. when intended for use as an antihistamine, and b. when intended for application to the skin, and c. when intended speci fically for the treatment of travel sickness. 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 46 Propantheline bromide. Propyphenazone. Proxymetacaine, when contained in eye drops intended for the emergency treatment of arc eyes. (S4) Pseudoephedrine, contained in products registered in terms of the Act, and not intended for export, a. Immediate -release oral preparations and mixtures containing not more than 60 milligrams of pseudoephedrine per dose or controlled -release oral preparations and mixtures containing not more than 120 milligrams of pseudoephedrine per dose, and not more than 240 milligrams per day, when in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, subje ct to a maximum pack size of 720 milligrams and limited to one pack per customer. (S6) Pyrobutamine. Quinine, preparations and mixtures containing not more than 1 percent thereof. (S4) Rabeprazole, when intended for the temporary short term relief of heart burn and hyperacidity, subject to - a. maximum daily dose of 10 milligrams; b. maximum treatment period of 14 days. (S4) Ranitidine, when administered orally for short -term symptomatic relief of heartburn and hyperacidity, subject to - a. a maximum dose of 75 milli grams; b. a maximum daily dose of 300 milligrams; c. a maximum treatment period of two weeks. (S3) Reproterol, except when contained in respirator solutions. (S3) Rimiterol, except a. when contained in respirator solutions (S3) and b. when intended for injection. (S4) Rotavirus, live attenuated. Rubella vaccine. Rupatidine. Sabadilla alkaloids; substances, preparations and mixtures containing 1 percent or more thereof. Salbutamol, except a. when contained in respirator solutions; (S3) and b. when intended for injection. (S4) Salmefamol, except DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 47 a. when contained in respirator solutions; (S3) and b. when intended for injection. (S4) Siccanin, when intended for application to the skin. Sodium cromoglycate, except when intended for veterinary use. (S4) Strychnine, preparations and mixtures containing 0,2 percent or less thereof. (S4) Sulfadiazine silver when intended for application to the skin in the short -term treatment of minor burns, provided that the pack size is limited to a maximum of 50 grams. ( S4) Sulphonamideswhen intended for application to the eyes, nares and vagina; (S4) p-Synephrine, a. oral preparations and mixtures registered in terms of the Act and intended for the symptomatic relief of nasal and sinus congestion, where the recommended daily dose for adults is more than 50 milligrams and for children 6 to 12 years is more than 25 milligrams; (S6) b. except preparations and mixtures registered in terms of the Act and intended for application to the skin, ears and nares containing 1 percent o r less of p -synephrine and containing 0,2 percent or less for application to the eyes; (S0) c. except oral preparations and mixtures registered in terms of the Act and intended for the symptomatic relief of nasal and sinus congestion, where the recommended da ily dose for adults is 50 milligrams or less and for children 6 to 12 years is 25 milligrams or less, with a maximum pack size of 5 days. (S1) Terbutaline, except when contained in respirator solutions. (S3) Tetanus toxoid, Tetanus vaccine. Tetracaine, a. when contained in eye drops intended for the emergency treatment of \"arc eyes\" b. except when intended for topical use; (S1) c. except in oral preparations containing 2 percent or less of tetracaine, per dosage unit; (S1) d. except when intended for ophthalmic or parenteral use. ( S4) (S1) Thenalidine. Thenyldiamine. Theophylline and its derivatives, unless listed in another Schedule, and except in preparations for injection. (S4) Thiethylperazine. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 48 Tiaprofenic acid, when intended for the treatment of post -traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3) Timepidium. Triamcinolone, when intended for application solutions. (S3) Typhoid vaccine. Ulipristal. Vitamin A and derivatives thereof and including retinol, retinal, retinoic acids and beta -carotene (but excluding isotretinoin) and not listed elsewhere in the Schedules, contained in preparations or mixtures containing more than 5 000 I.U (or 1 500 milligrams of the retinol equivalent or 3 000 milligrams of the beta -carotene equivalent) but not more than 10 000 I.U (or 3 000 milligrams of the retinol equivalent or 6 000 milligrams of the beta -carotene equivalent) of Vitamin A per recommended daily dose alone or in combination with other active pharmaceutical ingredients, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agriculture Remedies and Stock Remedies Act, 1947 (Act 36 of 1947 ). (S0, S3) Vitamin E and derivatives thereof, including dl-alpha -tocopherol and not listed elsewhere in the Schedules, contained in preparations or mixtures containing more than 400 I.U. of Vitamin E per recommended daily dose. (S0) Xylometazoline, except when intended for nasal ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 49 ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduat es only) registered with Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates only) ANTI -CHOLINERGIC Substance : Ipratropium b romide Indication : Inhalant Bronchodilator (atropine derivative anti-cholinergic) Route of Administration : Respirator Solution SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Bronchodilator Route of Administration : Aerosol NON -STEROIDAL ANTI -INFLAMMATORY Substance : Ibuprofen Indication : Analgesic/ Anti-inflammatory Route of Administration : Oral ANALGESIC Substance : Paracetamol Indication : Analgesic/ Anti -pyrexia Route of Administration : Oral ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) ANTI -CHOLINERGIC Substance : Ipratropium bromide Indication : Inhal ant Bronchodilator (atropine derivative anti -cholinergic) Route of Administration : Respirator Solution SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Bronchodilator Route of Administration : Aerosol ANTI -SPASMODIC DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 50 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) Substance : Hyoscine butylbromide Indication : Anti-spasmodic Route of Administration : Oral ANTI -PROPULSIVE Substance : Loperamide Indication : Symptomatic management of diarrhoea in adults Route of Administration : Oral NON -STEROIDAL ANTI -INFLAMMATORY Substance : Ibuprofen Indication : Analgesic/ Anti -inflammatory Route of Administration : Oral ANALGESIC Substance : Paracetamol Indication : Analgesic/ Anti -pyrexia Route of Administration : Oral ANNEXURE 1C: BASIC AMBULANCE ASSISTANT BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa *ANTI -CHOLINERGIC Substance : Ipratropium bromide Indication : Inhalant Bronchodilator (atropine derivative anti -cholinergic) Route of Administration : Respirator Solution *SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Route of Administration Aerosol DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 51 ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa ANTI -CHOLINERGIC Substance : Ipratropium bromide Indication : Inhalant Bronchodilator (atropine derivative anti -cholinergic) Route of Administration : Respirator Solution SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Bronchodilator Route of Administration : Aerosol ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa ANTI -CHOLINERGIC Substance : Ipratropium bromide Indication : Inhalant Bronchodilator (atropine derivative anti -cholinergic) Route of Administration : Respirator Solution SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Bronchodilator Route of Administration : Aerosol ANNEXURE 1F: EMERGENCY CARE ASSISTANT EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa ANTI -CHOLINERGIC Substance : Ipratropium bromide Indication : Inhalant Bronchodilator (atropine derivative anti -cholinergic) Route of Administration : Respirator Solution SELECTIVE 2 AGONISTS Substance : Salbutamol Indication : Bronchodilator Route of Administration : Aerosol DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 52 ANNEXURE 2: DENTAL THERAPIST DENTAL THERAPIST (Bachelors degree in Dental Therapy) registered with Health Professions Council of South Africa DENTAL THERAPIST (Bachelors degree in Dental Therapy ) ANALGESIC, ANTIPYRETIC, ANTI INFLAMMATORY Substance : Ibuprofen Indication : Dental pain Route of Administration : Oral ANALGESIC, ANTIPYRETIC, ANTI INFLAMMATORY Substance : Codeine Indication : Dental pain Route of Administration : Oral ANTI -FUNGALS Substance : Nystatin Indication: : Candidal infections of the oral cavity Route of Administration : Oral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 2 53 ANNEXURE degree in Optometry - B OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber. OPTOMETRIST ANTIBACTERIAL Substance Hordeolum, Infected atopic dermatitis Route of Administration : Topical application ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER Substance : Antazoline Indication : Allergic and Atopic Conjunctivitis Route of Administration : Topical application ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER Substance : Tetrazoline Indication : Minor ocular irritation; Red eye Route of Administration : Topical application ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER Substance : Oxymetazoline Indic ation : Minor ocular irritation; Red eye Route of Administration : Topical application ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER Substance : Cetirizine; Loratidine; Levocetirizine Indication : Atopic dermatitis involving the eyelids Route of Administration : Oral ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER Substance : Sodium Cromoglycate Indication : Vernal Kerato conjunctivitis Route of Administration : Topical application STEROIDAL ANTI INFLAMMATORY Substance : Hydrocortisone Indication : Dermatitis, Ectopic or Seborrhoeic Eczema Route of Administration : Topical application - END SCHEDULE 2 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 54 SCHEDULE 3 a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and (ii) analytical laboratory purposes. b. All preparations of substances or mixtures of such substances contai ning or purporting to contain any substance referred to in this Schedule and include s the following: (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and (ii) all preparations and mixtures of such substances w here such preparations and mixtures are not expressly excluded. c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic); (ii) Annexure 1B: Emergency Care Provider (Em ergency Care Practitioner) ; (iii) Annexure 2: Dental Therapist; (iv) Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 55 a. when intended for injection or for the management of paracetamol overdosage; b. except when used as a mucolytic in acute respiratory conditions for a maximum treatment period of 14 days. (S1) Acipimox. Aclidinium. Adapalene. Adrenaline (epinephrine); acid. Ascorbic Acid -see Vitamin C. Atenolol. Atropine, a. when intended for use in ophthalmic preparations; (S2) b. except when intended Balsalazide. nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurised aerosol, and indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 56 a. a maximum dose of 100 micrograms per nostril and a maximum daily dose of 200 micrograms of per nostril and b. a maximum pack size S4) Benazepril. Bendazac. Benfluorex. Benoxaprofen. Benzbromarone. Benzydamine, except preparations and mixtures - a. containing 3 percent or less of benzydamine, when intended for application to the skin; (S0) b. intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine pe r day; (S1) c. containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)\" d. intended for human vaginal use. (S2) Bepridil. Bezafibrate. Bisoprolol. Bopindolol. for the management of faecal impaction, or for the purpose of bowel cleansing prior to surgical or diagnostic procedures, unless listed elsewhere in the Schedules. (S0) Brimonidine. Brinzolamide. DocuSign Envelope ID: when intended inhalation or nasal administration, unless listed in another Schedule. (S4) b. except when intended for the prophylaxis and treatment of seasonal and perennial allergic rhinitis in adults and children aged 12 years and older. (S2) Bufexamac, except when intended for application to the skin. (S1) Buflomedil. Buform in. Bumetanide. Butecosone, when intended for inhalation nasal administration. Cadralazine. Caffeine, when intended for injection. Calcipotriol. Calcium carbimide. Calcium, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S1) c. except when indicated for the treatment of hyperphosphataemia; (S4) d. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Calcium disodium edetate, when intended for injection. Calcium dobesilate. Candesartan. (S4) Carbamazepine. Carbenoxolone, except when intended for application to the oral mucosa. (S0) Carbuterol, when Cilomilast. Cimetidine, except when intended for the short -term symptomatic relie f of heartburn, dyspepsia and hyperacidity, subject to a maximum unit dose of 200 milligrams, a maximum daily dose (per 24 hours) of 800 milligrams and a maximum treatment period of 2 weeks. (S2) Clofibrate. Clonidine except when intended (S2 ) Clopidogrel. Codeine (methylmorphine), a. oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit, when contained in products registered in terms of the Act, and not intended for export; b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, when contained in products registered in terms of the Act, and not intended for export; DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 59 c. except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days and limited to one pack per customer, when contained in products r egistered in terms of the Act, and not intended for export ; (S2) d. except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export ; (S2) e. except single component codeine preparations. (S6) Colchicine, except when intended for the emergency treatment of acute gout, subject to a maximum total treatment course of 6 milligrams. (S2) Colestipol. Copper, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 4 mg of Copper per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1) Corticosteroids (natural or synthetic), except when listed separately in the Schedules, when contained in preparations intended for inhalation or n (Pyrethroid), except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). 3 60 a. except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0) b. except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1) c. except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2) d. except when intended for human use only in the treatment of fever or mild to m oderate pain of inflammatory origin, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days. ( S2) Dienogest. Diflunisal. Diftalone. Digitalis, its glycosides and other active principles thereof, unless diluted below one unit (BP) in each 2,0 grams. (S0) Dihydrocodeine, a. oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of dihydrocodeine (calculated as base) per dosage unit, when contained in products re gistered in terms of the Act, and not intended for export; b. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of dihydrocodeine (calculated as base) per 5 millilit re dosage unit, when contained in products registered in terms of the Act, and not intended for export; c. except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of dihydroc odeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days; (S2) d. except liquid oral preparations and mixtures, in combinati on with one or more therapeutically active substances, containing not more than 10 milligrams of dihydrocodeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres; (S2) e. except single component dihydrocodeine preparations. intended for oral contraception; b. except when intended for hormone Escin (aescin), except preparations and mixtures thereof intended for application to the skin and containing 1 percent or less of escin. (S1) Esculin, when intended for oral use. Esmolol. Estradiol, a. when intended for oral contraception; b. except when intended for human vaginal use; (S2) c. except when intended for hormone replacement 3 62 Etofenamate, except when intended for application to the skin. (S1) Etofenprox (Pyrethroid), except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Etoricoxib. Exenatide Felbamate. Felbinac, except when intended for Felodipine. Fenbufe n. Fenclofenac. Fendiline. Fenofibrate. Fenoprofen, a. except when intended for the emergency treatment of acute gout attacks, (S2) and b. when intended for the treatment of post traumatic conditions, for a maximum treatment period of 5 days. (S2) Fenoterol, wh en contained in respirator solutions. (S2, S4) Fentiazac. Fenticonazole, except when to the skin. (S1) Firocoxib. Floctafenine. Flufenamic acid, except preparations and mixtures intended for application to the skin. (S1) Flunisolid e, when intended for inhalation or nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurised aerosol, in a strenghth not exceeding 0,025 percent (m/v), and indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to a. a maximum dose of 50 micrograms per nostril and a maximum daily dose of 100 micrograms of per nostril in the case of adults and children over 16 years of ag e; b. a maximum dose of 25 micrograms per nostril and a maximum dose of 75 micrograms in children 12 to 16 years of age c. a maximum pack size of 2400 doses. (S2, S4) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 63 Flunixin. Fluorescein, except when intended for ophthalmic use by the topical route only . (S1) Flurbiprofen, except a. when intended for the treatment of post -traumatic conditions, for a maximum period of 5 days;(S3) b. when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i). a maximum of 8,75 milligrams per lozenge; (ii). a maximum treatment period of 3 days; and (iii). a maximum pack size of 15 lozenges. (S1) b. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation , provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0) c. when intended for the treatment of post -traumatic cond itions, for a maximum period of 5 when intended for ophthalmic use; when intended for nasal administration; b. except when intended for nasal administration, as an aqueous spray in the short -term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2) c. except when intended for administration other than by inhalation or nasal administration. (S4) Fluticasone administrati on; b. except when intended for nasal administration as an aqueous spray in the short -term (less than 6 months prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 100 micrograms per nostril; and (ii) a maximum pack size of 120 doses. (S2) c. except when intended for administration other than by inhalation or nasal preparations and mixtures when intended for the treatment of primary and secondary osteoarthritis, osteochondrosis and spondylosis , except when registered as a feed supplement in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Glutathione, when intended for intravenous infusion ophthalmic preparations thereof. (S2) Hormones (natural or synthetic, including recombinant forms), with either hormonal, prohormonal or anti - hormonal action, unless li sted elsewhere in the schedules, a. when intended for oral contraception; b. except when intended for human vaginal use (S2), and c. except hormones when specifically intended for tal contraception. (S2, S4, S5) Hydralazine. (S2) DocuSign Envelope opthalmic use (S0) Hyoscine butylbromide; substances, preparations and mixtures thereof - a. except when intended for oral administration; (S1, S2) and b. except transdermal preparations when intended for the prevention of the symptoms of motion sickness. (S2) Ibuprofen, except a. when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen; (S0, S1) b. when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided do ses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post -traumatic conditions in adults and children over 12 years of age where t he recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1) c. when contained in oral medicinal preparations intended for human use o nly, in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2) d. when contained in oral medicinal preparations, intended for human u se only, as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post -traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2) e. for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S2) f. when intended for the treatment of haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age. (S4) Imepitoin, when intended for veterinary use. Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 66 Indometacin, except a. for application to the skin (S1), and b. for the emergency treatment of acute gout attacks (S2). Indoprofen. Indoramin. Injections, unless listed in another Schedule. Insulin. Insulin aspart. Insulin degludec. Insulin glargine. Ipratropium, when contained in respirator solutions. (S2) Irbesartan. Iron, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 24 mg of Iron per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S1) c. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Isoprenaline (isoproterenol), when registered as an anthelmintic and/or ectoparasiticide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Re medies Act, 1947 (Act 36 of 1947). Ketanserin. Ketoprofen, a. except when intended for application to the skin; (S1) b. except when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhoea), DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 67 minor aches and pains associated with the common cold and fever, subj ect to a maximum dose of 75 milligrams of ketoprofen in 24 hours; (S2) c. except when intended for the emergency treatment of acute gout attacks or for the treatment of post - traumatic conditions, subject to a maximum dose of 75 milligrams of ketoprofen per da y and a maximum treatment period of 5 days; (S2) d. except in the form of lozenges indicated and intended for the relief of pain associated with sore throats in patients 18 years and older subject to - (i) a maximum of 12,5 milligrams per lozenge; (ii) a maximum of 5 l ozenges in any 24 hour period; (iii) a maximum treatment period of 3 days; and (iv) a maximum pack size of 15 lozenges. (S2) Ketorolac, for oral contraception b. except when intended for emergency post coital contraception; (S2) c. excep t used for faecal impaction, or for the purposes of bowel cleansing prior to surgery or diagnostic procedures, e xcept when intended for the treatment of constipation , (S0). Meclofenamic acid. Mefenamic acid, except - a. when intended for the treatment of post -traumatic conditions, for a maximum period of 5 days; and b. preparations containing mefenamic acid as the only therapeutic active substance, when intended for human use only in the treatment of primary dysmenorrhoea subject to a maximum daily dose of 500 millligrams mefenamic acid 3 times a day and a maximum treatment period of 3 days. (S2) Meloxicam. Mepindolol. Mesalazine or nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 69 a. a maximum dose of 200 microg rams per nostril in adults and 50 micrograms per nostril in children; and b. a maximum pack size of 200 doses. (S2, S4) Montelukast. Moxonidine. Nabumetone, except whe n intended for the treatment of post -traumatic conditions, for a maximum treatment period of 5 days. (S2) Nadolol. Naftidrofuryl. Naproxen, except a. when contained in preparations intended for application to the skin; (S1, S2) b. when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origin at a maximum do se of 600 milligrams naproxen base (660 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the stated maximum treatment peroid. (S1, S 2) c. when intended for the treatment of acute gout attacks, for a maximum treatment period of 5 days in patients over 16 years of age. (S1, S2) Nateglinide. Nebivolol. Nepafenac. Nicardipine. Nicotine, a. when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended); b. except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges contai ning not more than 4 mg nicotine per piece; (S0) c. except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; (S1) d. except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21 mg/ 24 hours or 25 mg/ 16 hours; (S2) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 70 e. except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2) f. except when registered as metered sprays containing not more than 1 mg per dose; (S2) g. except when registered as oral solid dosage forms containing not more than 2 mg; (S2) h. except when registered as inhalers containing not more than 10 mg per cartridge. (S2) Nifedipine. Niflumic acid. Nimodipine. - see Theodrenaline. Norelgestromin. Norethisterone, a. when intended for oral contraception; b. except when intended for parenteral use as a contraceptive; (S4) c. except when intended for hormone replacement therapy. (S4) Norgestrel, a. when intended for oral contraception; b. except when intended for hormone replacement therapy. (S4) Normal Saline (Sodium chloride 0,9 percent m/v) when intended for injection, except when intended for injection in a dosage form not exceeding 20 millilitres in volume. (S0, S1) Olsalazine. Olmesartan. Orlistat, except when used in a dose not exceeding 60 milligrams per main meal and not exceeding a maximum dose of 180 milligrams per 24 S1, S2) tetranitrate. Pentolinium. Pentosan (S1) Perindopril. Phenformin. Phen obarbital, preparations not more than 90 milligrams of phenobarbital per minimum recommended or prescribed dose when intended for continued use in epilepsy. (S5) Phenoxymethylpenicillin, when intended for the (S4) Phentolamine. Piretanide. Piroxicam, a. except when intended for the emergency treatment of acute gout attacks, (S2) or DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 72 b. when intended for the treatment of post -traumatic conditions, for a maximum treatment period of 5 days. (S2) Pirprofen. Potassium canrenoate. Potassium, a. when intended for intravenous infusion or for injection; b. except when contained in oral rehydration preparations; (S0) c. except in oral preparations or mixtures containing more than 20 millimoles (1500mg) of potassium per (lipido -sterolic complex extract thereof). Pyrazinamide, Ranitidine, except where administered orally for short -term symptomatic relief of heartburn and hyperacidity, subject to a maximum dose of 75 milligrams, a maximum daily dose of 300 milligrams and a maximum treatment period of two weeks. (S2) Raubasine. Rauwolfia or synthetic). Riboflavin -see Salbutamol, when contained in respirator solutions. see Silymarin. Silymarin , except when present in a complementary medicine with an accepted low risk claim or health claim, providing not more than 600 mg of Silymarin per day (calculated as silibinin/silybin). (S0) Sitagliptin phosphate. Sodium phosphate, in preparations intended for the management of faecal impaction o r for bowel cleansing prior to surgical and diagnostic procedures. (S0) Sodium picosulphate, in preparations intended for the management of faecal impaction or for bowel cleansing prior to surgical and diagnostic procedures. (S0) Solcoseryl; toothpaste. (S0) Strophanthus; its glycosides and their hydrolysis products, and their derivatives, unless listed in another Thiocolchicoside. Thyroid gland and its active principles and derivatives, unless listed in another Schedule. Tiagabine. Tiaprofenic acid, except when intended for the treatment of post -traumatic cond itions, for a maximum treatment period of 5 skin. (S1) Tolterodine. Topiramate. Torasemide. Trandolapril. Tretinoin, V. cholera. Valdecoxib. Valproic acid Vitamin B1 (Thiamine) and derivatives thereof, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1) Vitamin B2 (Riboflavin) and derivatives thereof, a. in pre parations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1) Vitamin B3 - See Niacin. Vitamin B 5 (Pantothenic Acid) and derivatives thereof, a. in preparations thereof for injection; (S0) b. in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredi ents. (S1) Vitamin B6 (Pyridoxine) and derivatives thereof, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active p harmaceutical ingredients. (S1) Vitamin B12 (Cyanocobalamin) and derivatives thereof, a. in preparations thereof for injection; (S0) b. except in oral preparations or mixtures containing more than 100 \u00b5g of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1) Vitamin C (Ascorbic Acid), a. in preparations thereof for injection; (S0) b. excep t in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1) Vitamin D (cholecalciferol), preparations thereof for injection and oral preparations and mixtures thereof containing more than 1 000 I.U. per recommended daily dose, except when registered in terms of the DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 77 provisions of the Fertilizers, Farm Feeds, Agricul tural Remedies and Stock Reme dies Act, 1947 (Act 36 of 1947). (S0) Vitamin K and derivatives thereof, a. in injection preparations; (S0) b. except in oral preparations or mixtures containing more than 120 \u00b5g of Vitamin K per recommended daily dose alone or in co mbination with other active pharmaceutical ingredients, (S1) c. except when used in infant milk feeds or formulae in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972). Water for injection except in a dosage form not exceeding 20 milliliters in volume. (S1) Xamoterol. Xipamide. Zafirlukast. Zinc salts, a. for oral ingestion, where the daily dose is more than 50 milligrams of elemental zinc; (S0), b. except preparations thereof for injection, when intended for veterinary use; (S1) and c. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Zomepirac. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 78 ANNEX URE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduates only) registered with Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates only) PLATELET AGGREGATION INHIBITOR Substance : Clopidogrel Indication : Platelet aggregation inhibitor Route of Administration : Oral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium c hloride Indication : Plasma expanders Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronchodilator Route of Administration : Inhalant SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Inhalant MINERAL SUPPLEMENT/ ELECTROLYTE Substance : Calcium c hloride Indication : Positive inotrope - peri-cardiac and cardiac arrest / Electrolyte / Mineral Supplement Route of Administration : Parenteral OTHER MINERAL SUPPLEMENT Substance : Magnesium sulphate Indication : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 79 PARAMEDIC (National Diploma in Emergency Medical Care graduates only) CARBOHYDRATES Substance : Dextrose Indication : Nutrition / Acute Symptomatic HypoglycaemicTreatment Route of Administration : Parenteral HIGH CEILING LOOP DIURETIC Substance : Furosemide Indication : Diuretic Route of Administration : Parenteral ORGANIC NITRATES Substance : Glyceryl t rinitrate Indication : Vasodilator Route of Administration : Oral ANTI -EMETIC Substance : Cyclizine Indication : Antihis tamine, anti -emetic Route of Administration : Parenteral CO-ENZYME Substance : Thiamine (Vitamin B1) Indication : Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi) Route of Administration : Parenteral ANALGESIC Substance : Paracetamol Indication : Analgesic/ Anti -pyrexia Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 80 ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) PLATELET AGGREGATION INHIBITOR Substance : Clopidogrel Indication : Platelet aggregation inhibitor Route of Administration : Oral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasm a expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium chloride Indication : Plasm a expanders Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronc hodilator Route of Administration : Inhalant SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Inhalant MINERAL SUPPLEMENT/ ELECTROLYTE Substance : Calcium c hloride Indication : Posit ive inotrope - peri cardiac and cardiac arrest / Electrolyte / Mineral Supplement Route of Administration : Parenteral OTHER MINERAL SUPPLEMENTS Substance : Magnesium sulphate Indication : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 81 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) CARBOHYDRATES Substance : Dextrose Indication : Nutrition / Acute Symptomatic Hypoglycaemic Treatment Route of Administration : Parenteral HIGH CEILING LOOP DIURETIC Substance : Furosemide Indication : Diuretic Route of Administration : Parenteral ORGANIC NITRATES Substance : Glyceryl t rinitrate Indication : Vasodilator Route of Administration : Oral ANTI -EMETIC Substance : Cyclizine Indication : Antihist amine, anti -emetic Route of Administration : Parenteral CO-ENZYME Substance : Thiamine (Vitamin B1) Indication : Nutri tional supplement / Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi) Route of Administration : Parenteral ANALGESIC Substance : Paracetamol Indication : Analgesic/ Anti -pyrexia Route of Administration : *ANTI -SPASMODIC Substance : Hyoscine butylbromide Indication : of Administration : Parenteral **ARTERIAL SMOOTH MUSCLE AGENT Substance : Hydralazine Indication : Hypertension in pregnancy Route of Administration : Oral BETA BLOCKER Substance : Labetalol Indication : Hypertension in pregnancy Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 82 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) **CLASS III ANTI -ARRHYTHMIC Substance : Sotalol Indication : Anti-arrhythmic Route of Administration : Oral/ Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of Administration : Parenteral **VASODILATOR Substance : Isosorbide dinitrate Indication : Acute pulmonary syndrome/ Acute pulmonary oedema Route of Administration : Parenteral ANNEXURE 1C: BASIC AMBULANCE ASSISTANT BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa *SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 83 ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium chloride Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of Administration : Parenteral *CARBOHYDRATES Substance : Dextrose Indication : Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics Route of Administration : Parenteral *CO-ENZYME Substance : Thiamine (Vitamin B1) Indication : Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi) Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 84 *OTHER MINERAL SUPPLEMENTS Substance : Magnesium sulphate Indication : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: Route of Administration : Inhalant ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium chloride Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 85 PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of Administration : Parenteral CARBOHYDRATES Substance : Dextrose Indication : Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics Route of Administration : Parenteral *CO-ENZYME Substance : Thiamine (Vitamin B1) Indication : Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi) Route of Administration : Parenteral OTHER MINERAL SUPPLEMENTS Substance : Magnesium sulphate Indication : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy, Ventricular anti -arrhythmic Route of Administration : Parenteral ORGANIC NITRATES Substance : Glyceryl trinitrate Indication : Vasodilator Route of Administration : Oral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronc ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 86 ANNEXURE 1F: EMERGENCY CARE ASSISTANT EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium chloride Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of Administration : Parenteral CARBOHYDRATES Substance : Dextrose Indication : Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 87 *CO-ENZYME Substance : Thiamine (Vitamin B1) Indication : Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi) Route of Administration : Parenteral OTHER MINERAL SUPPLEMENTS Substance : Magnesium sulphate Indication : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : degree in Optometry - B OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber. OPTOMETRISTS CYCLOPLEGICS Substance : Atropine Indication : Cyclopegic refraction; Treatment of Uveitis Route of Administration : Topical Application (Drops) MYDRIATICS/ CYCLOPLEGICS Substance : Tropicamide Indication : Cyclopegic; Mydriatic Route of Administration : Topical Application (Drops) MYDRIATICS/ CYCLOPLEGICS Substance : Cyclopentolate Indication : Cyclopegic; Mydriatic Route of Administration : Topical Application (Drops) MYDRIATICS/ CYCLOPLEGICS Substance : Homatropine Indication : Cyclopegic; Mydriatic Route of Administration : Topical Application (Drops) ANTI GLAUCOMA Substance : Pilocarpine Indication : Acute Glaucoma Route of Administration : Topical Application (Drops) ANTI GLAUCOMA Substance : Timolol Indication : Acute Glaucoma Route of Administration : Topical Application (Drops) BETA -BLOCKER Substance : Betaxolol Indication : Open -Angle Glaucoma in Adults Route of Administration : Topical Application (Drops) SYMPATHOMIMETIC Substance : Brimonidine Indication : Open -Angle Glaucoma in Adults Route of Administration : Topical Application (Drops) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 89 OPTOMETRISTS BETA -BLOCKER Substance : Levobunolol Indication : Open -Angle Glaucoma in Adults Route of Administration : Topical Application (Drops) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 3 90 ANNEXURE 4: PODIATRIST PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) PODIATRIST SYMPATHOMIMETIC Substance : Adrenaline / Epinephrine Indication : Sympath omimetic catecholamine for the management of shock Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Bupivacaine Hydrochloride 2 % Indication : Local Anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Bupivacaine Hydrochloride 2 % with Adrenaline Indication : Local Anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Levobupivacaine Hydrochloride with Adrenaline Indication : Local Anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Lidocaine (Lignocaine) Hydrochloride Indication : Local Anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Lidocaine (Lignocaine) Hydrochloride with Adrenaline Indication : Local Anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Mepivacaine Hydrochloride Indication : Local Anaesthesia Route of Administration : Parenteral - END SCHEDULE 3 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 91 SCHEDULE 4 a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal p urpose; and (ii) analytical laboratory purposes. b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and include s the following: (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded. c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority , to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner) Annexure 1C: Basic Ambulance Assistant Annexure 1D: Ambulance Emergency Assistant Annexure 1E: Emergency Car e Technician Annexure 1F: Emergency Care Assistant (ii) Annexure 2: Dental Therapist (iii) Annexure 3: salt, when intended for injection. Acyclovir, except when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S1) Adalimumab. Adenosine. Adrenaline, Alfa. Agalsidase beta . Alginic Acid, its salts and complexes thereof, when intended for use in gastric regurgitation, gastro -oesophageal reflux and reflux associated with hiatus hernia in infants and young children under the age of 6 years. (S0) Aglepristone. Alatrofloxacin. Albendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). -type listed elsewhere in the Schedules and except intra -mammary preparations thereof, containing tracer dye(s) and intended for the treatment of mastitis in cattle and registered in term s of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947. (Act 36 of 1947) Amprolium, except when listed elsewhere in the Schedules and except when intended and registered as an anti - coccidial preparation in te rms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947. (Act 36 of 1947) Amphotericin B Amprenavir. Anticoagulants, except preparatio ns intended for application to the skin. (S1) Antihemophilic factor. Antimalarials, unless listed elsewhere in the Schedules. Antimicrobial substances, natural or synthetic including substances purporting to be suitable for the treatment of microbial infections unless listed elsewhere in the Schedules, and except - a. the following substances when intended for topical application to the epidermis, nares and external (S1) b. when intended for use as - (i) disinfectants, being topical agents or preparations used to treat inanimate objects, materials or surfaces, and that destroys or inhibits the growth of pathogenic micro - organisms so treated in the non -sporing or vegetative state, rendering them harmful to neither health nor the quality of perishable goods; (S0) (ii) antiseptics, being topical agents or preparations used on skin and other living tissues, and that destroys or inhibits the growth of pat hogenic micro -organisms so treated in the non - sporing or vegetative state, protecting health and preventing infection; (S0) and (iii) germicides, being topical agents or preparations used to treat inanimate objects, materials or surfaces and/or on skin and other living tissues, destroying or killing pathogenic micro - organisms so treated in the non -sporing or vegetative state, thereby protecting health, the quality of perishable goods, and preventing infection. (S0) Antisera, unless listed elsewhere in the Schedul es when intended for veterinary use, except antisera registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Apixaban. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 95 Apomorphine, when indicated for the treatment erect ile intended and registered as an anticoccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Arsenamide, when intended for injection. Arsenic; a. when intended for injection; b. except in oral dosage form. (S1, co -formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2) Atracurium besilate. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 96 Atropine, a. when intended for use in injections. (S2) b. except when intended for use in ophthalmic preparations. (S3) Auranofin. Avilamycin, except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947(Act 36 of 1947). Avoparcin, except when listed elsewhere in the Schedules and except when intended and registered to pro mote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947(Act 36 application to the epidermis, nares and external ear. (S1) and except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947 ). Baclofen. Baloxavir. Bambermycin, except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remed ies Act, 1947 (Act 36 of 1947). Bariticinib. Barium sulfate. Basiliximab. Bazedoxifene. Beclomethasone dipropionate, (S3) Bedaquiline. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 97 Bee venom, ex cept preparations intended for application to t he use; b. except in lozenges containing 30 milligrams or less of benzocaine, per dosage unit; (S1) c. except when intended for topical use; (S1) d. except in preparations containing 2 percent the skin. (S1) Bimatoprost. Biolimus. Biological medicines, injectable preparations thereof, when intended for human use and unless listed elsewhere in the S chedules, a. except vaccines, when listed elsewhere in the Schedules and vaccines registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 98 b. but specifically including followi - (i) Equine anti -human thymocyte gamma globulin; (iii) anti -D immunoglobulin; (iv) Human anti -thymocyte rabbit immunoglobulin; (v) Hepatitis A vaccine; (vi) Hepatitis B immunoglobulin; (vii) Human normal immunoglobulin, possibly polyvalent or possibly including a. except when intended for the prophylaxis and treatment of seasonal and perennial allergic rhinitis in adults and children aged 12 years and older. (S2) b. except when intended for inhalation or nasal administration, unless listed in another Schedule. (S3) Bufenoide. Bumadizone. Bupivicaine. Buserelin. Busulfan. Butoconazole, except - a. when intended for application to the skin; (S1) and b. when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1) Cabergoline. Cabazitaxel. Calcitonin. Calcitriol. Calcium, a. when indicated for the treatment of hyperphosphataemia; (S0) b. except in oral preparations or mixtures containing more than1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutica l ingredients; (S1) c. except in preparations thereof for injection; (S3) d. except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Cambendazole , except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Canakinumab. Candicidin. Cannabidiol, except - a. in complementary medicines containing no more than 600 mg cannabidiol per sales pack, providing a maximum daily dose of 20 mq of cannabidiol, and making a general health enhancement, health maintenance or relief of minor symptoms (low -risk) claim; (S0) or DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 100 b. processed products made from cannabis raw pla nt material intended for ingestion containing 0,0075 percent or less of cannabidiol where only the naturally occurring quantity of cannabinoids found in the source material are contained in the product. (S0) Capsaicin, when intended for transdermal application. Capecitabine. Capreomycin. Carbachol, ophthalmic preparations thereof, when intended for glaucoma. (S3) Carbadox, except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Carbenicillin. Carbetocin . Carbidopa. Carglumic. Carmustine. Carnidazole, except when listed elsewhere in the Schedules and except injections thereof intended for use in pigeons and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Ac t 36 of when listed elsewhere in the Schedules and except injections thereof intended for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Chorionic gonadotrophin. Chymopapain, acid. Clazuril, except when intended and registered as an anti -coccidial preparation in terms of the provisio ns of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). veterinary use. Closantel, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Clotrimazole, except when intended for application to th e skin (S1) and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1) Cloxacillin, except when listed elsewhere in the Schedules and except intra -mammary preparations thereof, containing tracer dye(s) an d intended for the treatment of mastitis in cattle and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Cobicistat. Cobimetinib. Colfosceril. Colistimethate. Colistin , a. when presented as a finished pharmaceutical product; and b. except when compounded by a pharmacist in terms of Section 14(4) of the Act, by a veterinarian, or by a holder of a Section 22C(1)(a) licence, or presented as the raw material. (S6) Contrast media, unless listed elsewhere in the Schedules. Corifollitropin alfa. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 104 Corticosteroids (natural or synthetic), unless listed elsewhere in the Schedules, except - a. hydrocortisone and hydrocortisone acetate when used as a single active ingredient in a maximum concentration of 1,0 per cent in preparations intended for application to the skin; (S2) b. triamcinolone when intended for application to oral lesions; (S2) and c. when contained in preparations intended elsewhere in the Schedules. DocuSign Envelope ID: indicated for the treatment of hypertriglyceride levels. Decoquinate, except when listed elsewhere in the Schedules and except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). 4 106 a. except in preparations and mixtures when intended for application to the skin; (S0) b. except in preparations containing 0,5 percent or less of dichlorophen when inte nded for use in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972); c. except when intended for use and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedi es and Stock Remedies Act, 1947 (Act 36 of 1947). Diclazuril, except when intended registered as an anti -coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). elsewhere in the Schedules and except intra -mammary preparations thereof, containing tracer dye( s) and intended for the treatment of mastitis in cattle and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Dihydrotachysterol. Diiodohydroxyquinoline, except when i ntended and registered as an anti -coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). when listed elsewhere in the Schedules and except when intended for use in pigeons, as an anti -spirochaete preparation for pigs and to promote growth in terms of the provisions of the Fertilizers, Farm Feed s, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Diminazene, except when intended and registered as an antibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 107 Dinitolmide, except when listed elsewhere in the Schedules and except when intended and registered as an anti - coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 194 7). Dinitrophenol. Dinoprostone. Diphemethoxidine. Difenidol. Disophenol, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of application to the skin. (S5) Doxorubicin. Doxycycline, except a. when intended and labelled for the chemoprophylaxis of malaria in those aged 8 years and older . (S2) b. in preparations thereof for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remed ies Act, 1947 (Act 36 of 1947). Dronedarone. Drospirenone, DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 108 a. when intended for hormone replacement therapy; b. except when intended for Dupilumab. Durvalumab. Dutasteride. Dydrogesterone. Econazole, except a. when intended for application to the skin (S1) and b. when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1) Factor IX). Eicosapent (EPA) 460, when indicated for the treatment of hypertriglyceride levels. Eletriptan. Eltrombopag. Elvitegravir. Emetine, except substances, preparations and mixtures containing less than 0,2 percent of alkaloids, calculated as emetine. (S2) Empagliflozin. Emtricitabine Encainide. Enilconazole, Enoxacin. Enoxaparin. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 109 Enramycin, except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Enrofloxacin. Entacapone. Entecavir. Enzalutamide. alkaloids (natural or synthetic), except preparations and mixtures thereof when intended for the treatment for hormone replacement therapy; b. except when intended for human vaginal use; (S2) c. except when intended for Etiproston. Ethopabate, except when listed elsewhere in the Schedules and except when intended and registered as an anti - coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of short term sympt omatic relief of heartburn caused by excess acid, where the maximum dose is 10 milligrams, the maximum daily dose (per 24 hours) is 20 milligrams and the maximum treatment period is 2 weeks. (S2) Fampridine. Fazadinium. Febantel, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Fenchlorphos, except when registered in terms of the provisions of the Fertiliz ers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Fenoldopam. Fenoterol, when intended for the prevention or delay of labour, and preparations thereof for injection. (S2, S3) Fenticonazole. S3). Fluocinolone. Fluocinonide. Fluocortolone. Fluorides, a. except in oral medicinal preparations or mixtures intended for ingestion containing not more than 0,25 milligrams of fluorine per dosage unit; (S1) b. except in toothpaste containing not more than 0,15 percent fluoride; (S0) and c. except in mouth rinses containing not 0,15 percent fluoride. (S0) ophthalmic use; (S 4) b. except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 112 (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1) c. except when intended for application to the skin, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is l imited to a maximum of 4 weeks. (S0) d. except when intended for the treatment of post -traumatic conditions, for a maximum period of 5 days; (S2) Flutamide. Fluticasone furoate, except - a. when intended for nasal administration, as an aqueous spray , in the short -term (less than 6 months) prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 55 micrograms per nostril; and (ii) a maximum pack size limit of 120 doses. (S2) b. when intended for inhalation or nasal administration. (S3) Fluticasone propionate, except - a. when intended for nasal administration as an aqueous spray, in the short -term (less than 6 months prophylaxis and treatment of the symptoms of se asonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to - (i) a maximum daily dose of 100 micrograms per nostril; and (ii) a maximum pack size of 120 doses. (S2) b. when intended for inhalation or nasal Furaltadone, except when listed elsewhere in the Schedules and except when intended as a single oral dosage for gastro -intestinal infections and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Furazolidone. Fusidic acid, except when intended Gadodiamide. Gadofosveset. Gallamine. Gamithromycin. Gamma benzene hexachloride, except when intended to be used for the second line treatment of lice in a pack size not exceeding -sulphuric acid ester), application to the skin. (S1) Golimumab. Gonadorelin. Goserelin. Gramicidin except when intended for topical the epidermis, nares and external ear. (S1) Granisetron. Granulocyte Colony Stimulating Factor (G -CSF). Griseofulvin except when intended for topical application to the and external ear. when i ntended and registered as an anti -coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Halogenated hydroxyquinolines, except when intended for application to t he skin. (S2) Halometasone. Halquinol. Hemin. Heparin. Heptaminol. Hexoprenaline, when intended for the prevention or delay of labour and preparati ons thereof for injection. (S2, S3) Histrelin Hormones (natural or synthetic, including recombinant forms), with either hormonal, prohormonal or anti - hormonal action, unless listed elsewhere in the Schedules, and except - a. when specifically intended for emergency postcoital contraception; (S2) b. when intended for oral contraception; (S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 115 all forms; (S5) g. zeranol, natural estrogen, and progesterone, when intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). h. BST (Bovine somatropin), when intended and registered as a production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agric ultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Human coagulation factors. Human fibrinogen, when indicated for use as a haemostatic. Human normal immunoglobulin. Human Plasma. Human Plasma Proteins. Human thrombin, when indicated for use a s a haemostatic. Hyaluronidase. Hyaluronic acid and its salts, a. when intended for parenteral use; b. except when intended for use with contact lens solutions or as an ophthalmic lubricant in concentrations of not more than 0,1 percent; (S0) c. except when intended for topical application to the skin; (S1) d. except when intended for ophthalmic use in preparations (except injectables) containing more than 0,1 percent;(S2) e. except in preparations containing less than 2,5 percent when intended for topical use in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972). Hycanthone. 116 a. Ibuprofen, when intended for the treatment of a haemodynamically significant patent ductus arterious in infants less than 34 weeks of gestational age; b. except when contained in preparations intended for application to the skin; containing 5 % m/m or less of ibuprofen; (S0, S1) c. except when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderat e pain or fever of inflammatory origin or for the treatment of post -traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1) d. except when contained in oral medicinal preparations intended for human use only, in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2) e. except when contained in oral medicinal preparations, intended for human use only, as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum trea tment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post -traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and u p to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2) f. except for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S2) g. except when intended for veterinary use. (S3) Ibutilide. Ibritumomab. Ibrutinib. Idarubicin. Idarucizumab. Idoxuridine, except except when intended and registered as an antibabesial for the treatment of babesiosis in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of gamma. Intra-uterine devices. Intra-uterine systems, drug eluting, unless listed elsewhere in the Schedules. Intrifiban. Iobitridol. Iocarmic acid. Iodamide sodium. Iodised Isoconazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1) Isoniazid Isopirin. preparations and mixtures containing not more than 1,0 per cent of ketoconazole when intended for the prevention and treatment of dandruff; (S0) or b. when intended for application to the skin. (S0, S1) Ketorolac, except when intended Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 119 Lanreotide. Lansoprazole, except when intended for the temporary short -term relief of heartburn and hyperacidity, subject to - a. a maximum daily dose of 15 milligrams (S2); and b. a maximum treatment period (S2) Lanthanum. Lapatinib . Laronidase. Laropiprant. Lasalocid, except when listed elsewhere in the Schedules and except when intended and registered as an anti - coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies A ct, 1947 (Act 36 intended and registered as an anthelmintic and an immunomodulator in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Levobupivacaine. Levodopa. Levofloxacin. Levonorgestrel, a. when administered via an Intra Uterine System; DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 120 b. except when intended for oral contraception; (S3) c. except when intended for emergency post coital contraception. (S2) Levosimendan. or parenteral use; b. when intended for the treatment of neuropathic pain associated with previous herpes zoster infection; c. except when intended for topical use; (S1) d. except in oral preparations containing 2 percent or less of lidocaine per dosage ophthalmic or parenteral use except - a. when intended for topical use; (S1) b. oxybuprocaine, proxymetacaine and tetracaine when contained in eye drops intended Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 121 Lymecycline. Lysozyme, except preparations and mixtures when intended for application to the skin. (S1) Macitentan. Maduramicin, except when listed elsewhere in the Schedules and except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Mafenide. Mangafodipir trisodium. Mandelic acid. Maraviroc. veterinary use. Mavacoxib. Mecamylamine. Mecillinam. Medical gases, when used in combination with nitro us oxide, but excluding such medical gasses when used alone or in combinations that exclude when used for the treatment of desyncronosis (jet -lag) in doses not exceeding 6 milligrams daily. (S2). Melphalan and its derivatives, unless derivatives, unless listed in another Schedule. Mercury, preparations and mixtures that contain mercury metal and that are intended for medicinal use, except preparations of mercuric oxides containing less than 3 percent of mercury. (S2) Mesna, when intended for injection. (S2) Metaproterenol (orciprenaline), when intended for the prevention or delay of labour, an d preparations thereof for injection. (S2, S3) Metergoline. Methacholine. Methampyrone (dipyrone). Methenamine (hexamine), 123 Metronidazole, except when a. intended and registered for use in pigeons in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 19 47 (Act 36 of 1947) and b. intended for human vaginal use, specifically for the treatment of recurrent bacterial vaginosis. (S2) Mexiletine. Mezlocillin. Micafungin. Miconazole, a. except when intended for application to the skin; (S1) and b. except when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis; (S1) and c. except when intended for human use in preparations containing 2 per cent or less of miconazole, when intended for the topical treatment of fungal infections of the for application to the scalp in preparations containing not more than 2 percent (m/v) and which are registered in terms of the S3) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 124 Monensin except when listed elsewhere in the Schedules and except when intended and registered as an anti - coccidial preparation and as a feed additive for growth promotion in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). for topical application to the epidermis, nares and external ear. (S2) Mycophenolic acid. Mycoplasma gallisepticum (Strain F) vaccine, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Nadroparin. Nalidixic acid. Nalorphine. Naloxone. Naltrexone. Narasin except when listed elsewhere in the Schedules and except when intended and registered as an anti- coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Naratriptan. Natalizumab. Natamycin, except when intended for topical application to the epidermis, n ares and external ear. (S2) Nefopam. Nelfinavir. Neomycin , except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Neostigmine. DocuSign and derivatives thereof, a. when intended for hypercholesterolaemia and for the management of dyslipidaemias; (S0) b. except in oral preparations or mixtures containing more than 35 mg of Niacin per recommended da ily dose alone or in combination with other active pharmaceutical ingredients. (S1) Nicarbazin, except when intended and registered as an anti -coccidian preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of for application to the skin. (S1) Nitrofurazone, except when intended for application to the skin. (S1) Nitrofural, except preparations thereof intended for application to the skin. (S1) Nitrous oxide, alone or in combination with other medical gases. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 126 Nitrovin , except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Nitroxoline. Nitroxynil, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Nivolumab. Nizatidine, except when intended for ora l administration for short -term symptomatic relief of heartburn and hyperacidity, where the maximum dose is 150 milligrams, the maximum daily dose is 300 milligrams and the maximum treatment period is two weeks. (S2) Nomegestrol. Norethisterone, a. when int ended for parenteral use as a contraceptive; b. when intended for hormone replacement therapy; c. except when intended for oral contraception. (S3) Norfloxacin. Norgestrel, a. when intended for hormone replacement therapy; b. except when intended for oral contraception. (S3) Novobiocin. Nystatin, a. when intended for systemic use or the initial treatment of vaginal candidiasis; b. except when presented as oral drops containing not more than 100 000 I.U. per millilitre , (S2) c. except when intended for application to the skin, (S1) and d. except when intended for human vaginal use, specifically for the treatment o f recurrent vaginal candidiasis, (S1) e. except when intended and registered as a stock remedy for pigeons in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Obidoxime. Obinutuzumab. Oclacitinib. Ofloxacin. Olaquindox, except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Olaratumab. Oleandomycin. Olodaterol . Omalizumab. Omeprazole, except when intended for the temporary, short -term relief of heartburn ans hyperacidity, subject to: a. a maximum daily dose of 20 milligrams b. a maximum treatment period of 14 days. (S2) Ondansetron. Oprelvekin. Orbifloxacin. Ornidazole, except when intended for application to the skin. (S1) Ornipressin. Orphenadrine, except when contained in preparations intended for use as a muscle relaxant. (S2) Osaterone, when intended for veterinary use. Oseltamivir. Osimertinib. Oxamniqui ne. Oxfendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Oxacillin. Oxaliplatin. Oxetacaine (Oxethazaine), a. when intended for ophthalmic or parenteral use; b. except in oral preparations containing antacid. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 128 when intended for ophthalmic or parenteral use; b. except when contained in eye drops intended for the emergency treatment of \"arc eyes\". (S2) Oxyclozanide, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies A ct, 1947 (Act 36 of 1947). Oxyphenbutazone , except when intended and registered for the synchronization of oestrus in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947) Oxytetracycline, except when listed elsewhere in the Schedules and except preparations thereof for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947) intended for the temporary short -term relief of heartburn and hyperacidity, subject to: a. a maximum daily dose of 20 milligrams (S2); and b. a maximum treatment period 4 129 Penciclovir, except when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S1) Penethamate hydriodide, except when listed elsewhere in the Schedules and except intra -mammary preparations thereof, containing tracer dye(s) and intended for the treatment of mastitis in cattle and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Penicillamine. Pentamidine. Pentostatin. Perfluorooctane, Perhexiline. Pertuzumab. Phenacetin, except preparations and mixtures intended for external use and containing not more than 0,1 percent phenacetin as stabilizer. Phenamidine, except when intended and registered as an an tibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Pheneticillin. Phenindione. Phenopyrazone. Phenoxybenzamine. Phenoxymethylpenicillin, except when intended for the of rheumatic fever. (S3) Phospholipids when intended for parenteral administration. (S0) Phthalylsulfathiazole. Physostigmine, except preparations for glaucoma. (S3) Picrotoxin. Pilocarpine, except ophthalmic preparations in, preparations and mixtures containing more than 20 per cent of podophyllum resin. (S1) Polydimethylsiloxane see Silicone oil. Polyglycerylene -dextran. Polymixin B, except when intended for topical application to the epidermis, nares and external ear. (S1) Polynoxylin. Polysterene sulfonic Poractant alpha. Posaconazole . Potassium dichromate, except preparations and mixtures containing not more than 15 micrograms of potassium dichromate per dosage unit. Pradofloxacin, when veterinary use. Pralidoxime. Pramipexole. Prasugrel. Pravastatin. Praziquantel, exce pt when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Prednisolone. Prilocaine, a. when intended for ophthalmic or parenteral use; (S 4) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 131 b. except in topical preparations containing 10 percent or less of prilocaine. (S1) Primaquine. Procainamide. Procaine benzylpenicillin, except when listed elsewhere in the Schedules and except intra -mammary preparations thereof, containing tracer dye(s) and intended for the treatment of mastitis in cattle and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Reme dies and Stock Remedies Act, 1947 (Act 36 of 1947). Procarbazine. Progesterone. Proguanil, except b. when co -formulated with atovaquone and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2) Propafenone. Propentofylline, except when intended for veterinary use. (S1) Propylhexedrine, except when used as a vasoconstrictor and decongestant in nose preparations and inhalants. (S1) Protein C (isolated from human plasma). Proyliodone. Proteolytic (fibrinolytic ) enzymes, when intended for injection, and unless listed elsewhere in the Schedules. (S1) Protionamide. Proxymetacaine, except when contained in eye drops intended for emergency treatment of arc not more than 1 percent. (S2) Quinoronium, except when intended and registered as an antibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricul tural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 132 Quinupristin. Rabeprazole, except when intended for the temporary short term relief of heartburn and hyperacidity, subject to - a. maximum daily dose of 10 milligrams; b. maximum treatment period of 14 days. (S2) Ractopamine. Radiopharmaceuticals, being radioactive compounds and radio -active labelled compounds when used for diagnostic or therapeutic purposes, unless listed elsewhere in the Schedules, and including the following radioisotopes: (i) Chromium -51; (ii) 14 C - Urea; (iii) 18F - Fludeoxyglucose (2 - deoxy - 2 - [18F] - D- glucose (iv) Gallium -67; - 198. Rafoxanide, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Raltegravir. Raltitrexid . when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of listed elsewhere in the Schedules and except injections thereof intended for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Romiplostim. DocuSign (S2, S3) R-salbutamol, except when intended and registered as a stock remedy in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Salinomycin, except when listed elsewhere in the Schedules and except when intended as an anti -coccidial preparation and to promote growth and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Salmefamol, when intended intended and registered for the control of ticks and fleas in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Secukinumab. Selegiline. Selenium, a. in preparations thereof for injection when intended for veterinary use; b. except in oral preparations or mixtures containing more than 200 \u00b5g of Selenium per recommended daily dose alon e or in combination with other active for application to the skin. (S1) Sertindole. Sevelamer. Sildenafil. Silicone oil (polydimethylsiloxane) (S2) Sodium dih ydroazapentacene polysulphonate. Sodium fluoride; except oral medicinal preparations and mixtures thereof containing 40 milligrams or more per daily dose. (S1) Sodium nitroprusside. Sodium polystyrine sulphonic acid when indicated for therapeutic use. Sofosbuvir. Solcoseryl, except preparations intended for application to the skin, to the mucous membranes of the mouth and to the lips and except ophthalmic preparations thereof. (S0, S3) Sorafenib. Sparfloxacin. Spectinomycin. Stavudine. Stents, Eluting, Schedules. Streptokinase. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 136 Strychnine, except - a. preparations and mixtures containing 0,2 per cent or less of strychnine; (S2) and b. subject thereto that it shall only be supplied for the control of problem predatory m ammals - (i) on a written prescription issued by a State Veterinarian, for use in the particular State Veterinarian's area of jurisdiction, and in a quantity not exceeding 5 grams; and (ii) subject to the State Veterinarian obtaining prior written approval for su ch use from the Director of the concerned provincial conservation institution or authority in his area of jurisdiction, a copy of such written approval being attached to the written prescription Styramate. Sugammadex. Sulbactam. Sulfabenzamide. Sulfacetamide. Sulfadiazine, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfadiazine silver, except when intended for application to the skin in the short term treatment of minor burns, provided that the pack size is limited to a maximum of 50 grams; (S2) Sulfadimidine (sulfadimethoxine) except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock R emedies Act, 1947 (Act 36 of 1947). Sulfamethazine except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfadoxine except when registered in terms of the pro visions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfafurazole (sulfisoxazole). Sulfaguanidine except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfamethizole. Sulfamethoxazole except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfametopyrazin e. Sulfamoxole. Sulfanilamide. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 137 Sulfathiazole, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sulfisomidine. Sulfamerazine. Sulfapyridine. Sulfasalazine. Sulfonamides, unless listed elsewhere in the Schedules, and except - a. substances, preparations and mixtures intended for application to the eyes, nares and vagina; (S2) and b. when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricul tural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Sultamicillin. Sumatriptan. use; b. except when intended for topical use; (S1) c. except in oral preparations containing 2 percent or less of Tetracaine; (S1) d. except when contained in eye drops intended for the emergency treatment of \"arc eyes\". (S2) Tetracosactrin (Tetracosactide). Tetracycline, except when listed els ewhere in the Schedules and except injections thereof intended for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tetramisole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 139 Thalidomide. Theophylline and its derivatives, unless listed elsewhere in the S chedules, and preparations intended for injection. (S2) Thiamphenicol. Thioacetazone. Thiabendazole, except - a. when intended for application to the skin; (S1) and b. when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tioguanine. Tipiracil. Thiostrepton. Thymopentin. Thyrotropin alfa. Tiamulin, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tibolone. Ticarcillin. Tigecycline. Tildipirosin, when intended Tin fluoride (stannous fluoride), when intended for injection. Tinidazo le. Tinzaparin. Tioconazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1) when intended and registered as an anti -coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 194 7). intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Thiotepa. Trifluridine. Trimetaphan. Trimethoprim, except when specifically i ntended and registered in combination with sulphonamides for the treatment of gastro -enteritis and pneumonia in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tylosin, except when listed elsewhere in the Schedules and except when intended for addition to drinking water and feedstuff for administration to poultry and pigs and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tyropanoic acid. Tyrothricin, except when intended for topical application to the epidermis, nares and external ear. except when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of when listed elsewhere in the Schedules and except when intended and registered to promote growth as a feed additive in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Ziv-aflibercept. Zolmitriptan. Zoledronic ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduates only) registered with the Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates ) ANTI -ARRHYTHMICS Substance : Adenosine Indication : Endogenous Purine Nucleoside / Supraventricular Anti -arrhythmic Route of Administration : Parenteral ANTI -ARRHYTHMICS Substance : Amiodarone Indication : Class III Anti -arrhythmic / Atrial & Ventricular Route of Administration : Parenteral ANTI -ARRHYTHMICS Substance : Lignocaine h ydrochloride (Systemic) Indication : Class I B - Ventricular Anti -arrhythmic Route of Administration : Parenteral ADRENERGIC Substance : Adrenaline / Epinephrine Indication : Sympath omimetic catecholamine Route of Administration : Parenteral ANTI -CHOLINERGIC Substance : Atropine Indication : Com petitive Anti -Cholinergic, Bradycardia, Anti -arrhythmic Route of Administration : SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronchodilator Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral CORTICOSTEROIDS Substance : Hydrocortisone Indication : Gluco corticoid Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 144 PARAMEDIC (National Diploma in Emergency Medical Care graduates ) HYPERGLYCAEMIC AGENT Substance : Glucagon Indication of Administration Indication : Gluco corticoid / Anti -Inflammatory Route of Administration : Parenteral ANTI -EMETIC Substance : Metoclopramide m onohydrochloride Indication : Propulsive Anti-emetic / Dopamine Antagonist Route of Administration : Parenteral OPIOID Substance : Parenteral OPIOID ANTAGONIST Substance : Nitrous o xide Indication : Analgesic Gas Route of Administration : Inhalant *ANTI -FIBRINOLYTIC Substance : Tranexamic acid Indication : Major haemorrhage in trauma Route of Administration : Parenteral **OXYTOCIN Substance : Oxytocin Indication : Post-partum haemorrhage Route of Administration : Parenteral Substance : Prednisolone Indication : Glucocorticoid/ Steroidal anti -inflammatory Route of Administration : Oral LOCAL ANAESTHETIC Substance : Lignocaine hydrochloride Indication : Local anaesthesia Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 145 ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) ANTI -ARRHYTHMICS Substance : Adenosine Indication : Endogenous Purine Nucleoside / Supraventricular Anti -arrhythmic Route of Administration : Parenteral ANTI -ARRHYTHMICS Substance : Amiodarone Indication : Class III Anti -arrhythmic / Atrial & Ventricular Route of Administration : Parenteral ANTI -ARRHYTHMICS Substance : Lignocaine h ydrochloride (Systemic) Indication : Class I B - Ventricular Anti -arrhythmic Route of Administration : Parenteral ADRENERGIC Substance : Adrenaline / Epinephrine Indication : Sympathomimetic catecholamine Route of Administration : Parenteral ANTI -CHOLINERGIC Substance : Atropine Indication : Competitive Anti -Cholinergic, Bradycardia, Anti -arrhythmic Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronchodilator Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral CORTICOSTEROIDS Substance : Hydrocortisone Indication : Glucocorticoid / Steroidal Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 146 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) CORTICOSTEROIDS Substance : Methylprednisolone Indication : Glucocorticoid / Steroidal Anti -Inflammatory Route of Administration : AGENT Substance : Glucagon Indication : Hyperglycaemic agent of Administration : Parenteral ANTI -EMETIC Substance : Metoclopramide m onohydrochloride Indication : Propulsive Anti -emetic / Dopamine Antagonist Route of Administration : Parenteral OPIOID Substance : Parenteral OPIOID ANTAGONIST Substance : Nitrous o xide Indication : Analgesic Gas Route of Administration : Inhalant ( 50:50 combination with Medical Oxygen) THROMBOLYTIC AGENTS Substance : Streptokinase Indication : Enzymes Route of Administration : Parenteral THROMBOLYTIC AGENTS Substance : Tenecteplase Indication : Enzymes Route of Administration : Parenteral ANTITHROMBOTIC AGENTS Substance : Heparin s odium Indication : Anticoagulant Route of Administration : Parenteral ANTITHROMBOTIC AGENT Substance : Enoxaparin Indication : Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 147 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) MUSCLE RELAXANTS (NEURO BLOCKING AGENTS) Substance : Suxamethonium c hloride Indication : Depolarizing Muscle Relaxant Route of Administration : Parenteral MUSCLE RELAXANTS (NEURO BLOCKING AGENTS) Substance : Vecuronium Indication : Competitive Muscle Relaxant Route of Administration : Parenteral MUSCLE RELAXANTS (NEURO BLOCKING AGENTS) Substance : Rocuronium Indication : Non-Depolarizing Muscle Relaxants Route of Administration : Parenteral **CORTICOSTEROID Substance : Betamethasone Indication : Pre-term birth Route of Administration : Parenteral *ANTICHOLINESTERASE Substance : Neostigmine Indication : Reversal of neuromuscular blockade Route of Administration : Parenteral *CHOLINESTERASE INHIBITOR Substance : Sugammadex Indication : Reversal of neuromuscular blockade Route of Administration : Parenteral *SEROTONIN ANTAGONIST Substance : Ondansetron Indication : Post-operative nausea and vomiting Route of Administration : Parenteral *ANTI -FIBRINOLYTIC Substance : Tranexamic acid Indication : Major haemorrhage in trauma Route of Administration : Parenteral OXYTOCIN Substance : Oxytocin Indication : Post-partum haemorrhage Substance : Prednisolone DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 148 EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) Indication : Glucocorticoid/ Steroidal anti -inflammatory Route of Administration : Oral LOCAL ANAESTHETIC Substance : Lignocaine hydrochloride Indication : Local anaesthesia Route of Administration : Parenteral ANNEXURE 1C: BASIC AMBULANCE ASSISTANT BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa *SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 149 AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa *ADRENERGIC Substance : Adrenaline / Epinephrine Indication : Sympath omimetic catecholamine Route of Administration : *CORTICOSTEROIDS Methylprednisolone Indication : Glucocorticoid / Steroidal Anti -Inflammatory Route of Administration : Parenteral *CORTICOSTEROIDS Substance : Hydrocortisone Indication : Glucocorticoid / -Inflammatory Route of Administration : AGENT Substance : Glucagon Indication Administration : Parenteral ANTAGONIST hydrochloride Indication : Antagonist Administration : Parenteral OPIOID ANTAGONIST Substance : Nitrous oxide Indication : Analgesic Gas Route of Administration : Inhalant ( 50:50 combination with Medical Oxygen) SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Lignocaine hydrochloride Indication : Local anaesthesia Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 150 ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa ADRENERGIC Substance : Adrenaline / Epinephrine Indication : Sympath omimetic catecholamine Route of Administration : CORTICOSTEROIDS Methylprednisolone Indication : Glucocorticoid / Steroidal Anti -Inflammatory Route of Administration : Parenteral CORTICOSTEROIDS Substance : Hydrocortisone Indication : Glucocorticoid / -Inflammatory Route of Administration : AGENT Substance : Glucagon Indication : Hyperglycaemic agent of Administration : Parenteral ANTI -ARRHYTHMICS Substance : Amiodarone Indication : Class III Anti -arrhythmic / Atrial & Ventricular Route of Administration : Parenteral *ANTI -EMETIC Substance : Metoclopramide monohydrochloride Indication : Propulsive Anti -emetic / Dopamine Antagonist Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Salbutamol Indication: : Bronchodilator Route of Administration : Parenteral SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 151 ANTI -CHOLINERGIC Substance : Atropine Indication : Com petitive Anti -Cholinergic, Bradycardia, Anti -arrhythmic Route of Administration : hydrochloride Indication : Antagonist Administration : Parenteral OPIOID ANTAGONIST Substance : Nitrous oxide Indication : Analgesic Gas Route of Administration : Inhalant ( 50:50 combination with Medical Oxygen) **OXYTOCIN Substance : Oxytocin Indication : Post-partum haemorrhage Route of Administration : Parenteral Substance : Prednisolone Indication : Glucocorticoid/ Steroidal anti -inflammatory Route of Administration : Oral LOCAL ANAESTHETIC Substance : Lignocaine hydrochloride Indication : Local anaesthesia Route of Administration : Parenteral ANNEXURE 1F: EMERGENCY CARE ASSISTANT EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa *ADRENERGIC Substance : Adrenaline / Epinephrine Indication : Sympath omimetic Route of 4 152 CORTICOSTEROIDS Indication : Glucocorticoid / Steroidal Anti -Inflammatory Route of Administration : Parenteral CORTICOSTEROIDS Substance : Hydrocortisone Indication : Glucocorticoid / -Inflammatory Route of Administration : AGENT Substance : Glucagon Indication : Hyperglycaemic agent Route of Administration : Parenteral ANTI -CHOLINERGIC Substance : Atropine Indication : Com petitive Anti -Cholinergic, Bradycardia, Anti -arrhythmic Route of Administration : hydrochloride Indication : Antagonist Administration : Parenteral OPIOID ANTAGONIST Substance : Nitrous oxide Indication : Analgesic Gas Route of Administration : Inhalant ( 50:50 combination with Medical Oxygen) SELECTIVE 2 AGONISTS Substance : Fenoterol Indication : Bronchodilator Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Lignocaine hydrochloride Indication : Local anaesthesia Route of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 153 ANNEXURE 2: DENTAL THERAPIST DENTAL THERAPIST (Bachelors degree in Dental Therapy) registered with Health Professions Council of South Africa DENTAL THERAPIST (Bachelors degree in Dental Therapy ) LOCAL ANAESTHETIC Substance : Lignocaine / Lidocaine h ydrochloride 2 percent with Vasoconstrictor (Adrenaline) Indication : Dental local anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Lignocaine / Lidocaine hydrochloride 3 percent without a Vasoconstrictor (Adrenaline) Indication : Dental local anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Mepivacaine h ydrochloride 2 percent with a Vasoconstrictor (Adrenaline) Indication : Dental local anaesthesia Route of Administration : Parenteral LOCAL ANAESTHETIC Substance : Mepivacaine h ydrochloride 3 percent without a Vasoconstrictor (Adrenaline) Indication : Dental local anaesthesia Route of Administration : Parenteral ANTI -MICROBIALS (Beta -Lactams) Substance : Penicillins Indication : Dental orofacial and odontogenic infections (Non prophylactic) Route of Administration : Oral ANTI -PROTOZOAL Substance : Metronidazole Indication : Dental orofacial and odontogenic infections (Non prophylactic) Route of Administration : Oral AUTONOMIC SYMPATHOMIMETICS Substance : Adrenaline Indication : Emergency medicine for drug related anaphylactic shock Route of Administration : Parenteral DocuSign degree in Optometry - B OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber. OPTOMETRISTS ANTIBACTERIAL Substance Anterior blepharitis; Posterior blepharitis Route of Administration : Topical ANTIBACTERIAL Substance : Tetracycline Indication : Chlamydial conjunctivitis; Blepharitis Route of Administration : Topical Application : Erythromycin Indication : Chlamydial conjunctivitis; Blepharitis; Impetigo (Not to be used as 1st Line Treatment) Route of Administration : Topical Application ANTIBACTERIAL Substance : Aciclovir Indication : Conjunctivitis; Herpes simplex blepharitis; Epithelial keratitis Route of Administration : Topical Application LOCAL ANAESTHETIC Substance : Tetracaine Indication : Diagnostic Aide Route of Administration : Topical Application (Drops) LOCAL ANAESTHETIC Substance : Oxybuprocaine and other equivalent local anaesthetics Indication : Diagnostic Aide Route of Administration : Topical Application (Drops) ANTIBACTERIAL Substance : Tetracycline Indication : Trachoma Route of Administration : Oral ANTIBACTERIAL Substance : Doxycycline Indication : Trachoma Route of Administration : Oral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 4 155 OPTOMETRISTS ANTIBACTERIAL Substance : Azithromycin Indication : Trachoma Route of Administration : Oral -END SCHEDULE 4 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 156 SCHEDULE 5 AND SPECIFIED SCHEDULE 5 a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substa nce and /or exhibits pharmacodynamic properties similar to the listed substancereferred to in this Schedule include the following: (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and (ii) all preparations and m ixtures of such substances where such preparations and mixtures are not expressly excluded. (iii) all homologues of listed substances ( being any chemically related substances that incorporate a structural fragment into their structures that is similar to the st ructure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules. c. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and apply, only within his/her scope of practice and subject to the i ndication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 5 and Specified Schedule 5 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic); Annexure 1B: Emergency Care Provider (Emergency Care Practitioner) . Annexure 1E: Emergency Care Technician c. Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by ** Acitretin. excluding - amobarbital, cyclobarbital, pentobarbital and secobarbital (S6), and preparations and mixtures containing not more than 90 milligrams of phenobarbital** per minimum reco mmended or prescribed dose when intended for continued use in epilepsy. (S3) Benactyzine and its derivatives unless listed in another Schedule. Benfluramate. Benzoctamine. Benzodiazepines** and their derivatives**, unless listed e xcept flunitrazepam. (S6) Benzquinamide. Beta-aminopropylbenzene and beta -aminoisopropylbenzene: a. any compound structurally derived from either of these substances by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure); and b. any salt or substance falling under the above, and c. except preparations and mixtures of the above when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and d. except when contained in appliances for inhalation in which the substance is absorbed onto solid material; (S1, S7) and thereof; and DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 158 f. except S2, S6) Bolandiol. Bolasterone. 80 milligrams or more of bromine as bromide per recommended daily dose, except when specifically packaged, labelled and used for industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are int ended to be ingested by man or animals as food or applied to the body as a cosmetic and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 and for anaytical Schedule. Chlordiazepoxide**. Chlormethiazole. Chlormezanone, except mixtures thereof where the maximum recommended or prescribed dose does not exceed 100 milligrams of chlormezanone. (S2) Chloroform, all substances, preparations and mixtures containing more than 20 percent of chloroform. (S1), except for industrial purposes including the manufacturing and compounding of products not intended for medicinal use. antipruritic use. (S2) Danazol. Deanol and its derivatives, unless listed in another Schedule, except when specifically packaged, labelled and used for industrial purposes inc luding the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are intended to be ingested by man or animals as food or applied to the body as a cosmetic and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972, and for analytical laboratory for oral use containing not more than 135 milligrams of dextropropoxyphene, calculated as the base, per dosage unit or with a concentration of not more than 2,5 percent in undivided preparations. Dothiepin. Doxepin, except mixtures containing more than 20 percent of ether, (S1), except for industrial purposes including the manufacturing and compounding of products not intended for medicinal use. Ethinamate** and its de rivatives**, unless listed in another Schedule. Ethylestrenol. Etifoxine. Etodroxizine, except preparations and mixtures thereof when except when specifically packaged, labelled and used for industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are intended to be ingested by man or animals as food or applied to the body as a cosmetic and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972, and for anaytical laboratory purposes. Human growth hormone (human somatotropin) - all forms, whether natural or synthetic, including recombinant forms, with either hormonal, prohormonal or anti -hormonal action). 5-Hydroxy Tryptophan, a. except in oral preparations with a maximum daily dose not exceeding 220 mg of 5 -Hydroxy tryptophan, alone or in combination with other active pharmaceutical ingredients; (S1) b. except in oral preparation with a maximum daily dose not exceeding 220 mg of 5 -Hydroxy tryptophan alone or in combination with other active pharmaceutical ingredients, with general health claims as a health supplement. (S0) Hydroxyzine. Hygromycin B, except when listed elsewhere in the Schedules and except when intended as an anthelmintic for pigs and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultura l Remedies and Stock Remedies Act, 1947 (Act 36 of 1947) Imipramine and its derivatives, unless listed elsewhere in the Schedules. Iproniazid. Isoflurane. Isotretinoin. Lithium salts, except when DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 164 a. unless listed in another Schedule, b. except preparations and mixtures containing promethazine or dimethothiazine or their salts when used solely as an antihistaminic; (S2) and c. except preparations containing promethazine or its salts when intended specifically for the treatment of travel sickness or application to the skin; (S2) and d. except phenothiazine when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Phentermine**. Pimethixene, except preparations and mixtures thereof when used solely as an antihistaminic. (S2) Pimozide. Pipradrol**. Pizotifen, except pr eparations and mixtures thereof when used solely as an antihistaminic or when intended for thereof when specifically intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stoc k Remedies Act, 1947 (Act 36 thereof when specifically intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Tretinoin, when int ended for oral preparation. (S3) Triazolam**. Trimipramine. DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 166 L-Tryptophan, a. except in oral preparations with a maximum daily dose not exceeding 220 mg of L -tryptophan, alone or in combination with other active pharmaceut ical ingredients; (S1) b. except in oral preparation with a maximum daily dose not exceeding 220 mg of L -tryptophan alone or in combination with other active pharmaceutical ingredients, with general health claims as a 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduates only) registered with the Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates ) BENZODIAZEPINE DERIVATIVE Substance : Diazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE DERIVATIVE Substance : Midazolam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE DERIVATIVE Substance : Lorazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE ANTAGONIST Substance : Flumazenil Indication : Administration : Parenteral NON -SELECTIVE ANTIHISTAMINE Substance : Promethazine Indication : Antihistamine Route of Administration : Parenteral *INDUCTION AGENTS Substance : Ketamine Indication : Analgesia Route of Administration : Parenteral ANALGESIC INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 168 ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) BENZODIAZEPINE DERIVATIVE Substance : Diazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE DERIVATIVE Substance : Midazolam Indication : Antic -convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE DERIVATIVE Substance : Lorazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE ANTAGONIST Substance : Flumazenil Indication : Administration : Parenteral NON -SELECTIVE ANTIHISTAMINE Substance : Promethazine Indication : Antihistamine Route of Administration : Parenteral INDUCTION AGENTS Substance : Ketamine Indication : Dissociative Anaesthesia/Analgesic/Mild Bronchodilator Route of Administration : INDUCTION AGENTS Substance : Etomidate Indication : Induction Agent Route of Administration : Parenteral INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 169 ANNEXURE 1C: BASIC AMBULANCE ASSISTANT BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa ANALGESIC INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication : Analgesia Route of Administration : Inhalant ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa ANALGESIC INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication : Analgesia Route of Administration : Inhalant ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa BENZODIAZEPINE DERIVATIVE Substance : Diazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral *BENZODIAZEPINE DERIVATIVE Substance : Midazolam Indication : Antic -convulsant/Sedative/Hypnotic Route of Administration : Parenteral *BENZODIAZEPINE DERIVATIVE Substance : Lorazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE ANTAGONIST Substance : Flumazenil Indication : Administration : Parenteral NON -SELECTIVE ANTIHISTAMINE Substance : Promethazine Indication : of Administration : Parenteral DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 5 170 EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa ANALGESIC INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication : Analgesia Route of Administration : Inhalant ANNEXURE 1F: EMERGENCY CARE ASSISTANT EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa BENZODIAZEPINE DERIVATIVE Substance : Diazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral *BENZODIAZEPINE DERIVATIVE Substance : Midazolam Indication : Antic -convulsant/Sedative/Hypnotic Route of Administration : Parenteral *BENZODIAZEPINE DERIVATIVE Substance : Lorazepam Indication : Anti-convulsant/Sedative/Hypnotic Route of Administration : Parenteral BENZODIAZEPINE ANTAGONIST Substance : Flumazenil Indication : Benzodiazepine Antagonist : Parenteral INHALANT Substance : Methoxyflurane (Penthrox Inhaler) Indication : Analgesia Route of Administration : Inhalant - END SCHEDULE 5 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 6 171 SCHEDULE 6 a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following (unless expressly excluded or un less listed in another Schedule): (i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation; (ii) the esters and ethers of such substances and of the isomers referred to in (i) as well as the isomers of such esters and ethers, where the existence of isomers of such esters or ethers is possible; (iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible; (iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible; (v) all preparations and mixtures of any of the above. (vi) all homologues of listed substances ( being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules. b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply, only within his/her scope of practice and subject to the i ndication for use of such substances and medicines and to the conditions determined by the Authority , to patients under his/her care, the Schedule 6 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms o f the Act. (i) Annexure 1A: Emergency Care Provider (Paramedic); Annexure 1B: Emergency Care Provider (Emergency Care derivatives, being any compound structurally derived from either of these substances by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure); a. except preparations and mixtures of the above when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and b. except when contained in appliances for inhalation in which the substance is absorbed in solid material; (S1) and c. (S1, S2, S5) and d. except D-norpseudoephedrine ). Chlorodyne (Chloroform and Morphine Tincture BP 1980) or any preparation or mixture thereof described as chlorodyne. Chlorphentermine. Clonitazene. Coca leaf and any salt, compound, derivative or preparation of coca leaf and any salt, compound, derivative or preparation thereof that is chemically equivalent or identical to any of these substances, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis, except decocainized coca leaf and extractions of coca leaf where such extractions contain no cocaine or ecgonine. (S0) Codeine (methylmorphine), a. single component codeine preparations; b. oral solid prepa rations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3) c. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export. (S2, S3) Codoxime. Colistin, a. when compounded by a pharmacist in terms of Section 14(4) of the Act, by a veterinarian, or by a holder of a Section 22C(1)(a) licence, or presented as the raw material; and b. except when presented as a finished pharmaceutical product. (S4) Cyclobarbital. Desomorphine. Dexamfetamine (Dexamphetamine) in medicines registered in terms of the Act and intended for the treatment of Attention -Deficit Hyperactivity Disorder. (S7) Dextromoramide. Dextropropoxyphene, except preparations and mixtures for oral use containing 135 milligrams or less of dextropropoxyphene, calculated as the base, per dosage unit or with a concentration of not more than 2,5 percent in undivided preparations. single component dihydrocodeine preparations; b. oral solid preparations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3) c. liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparatio ns not registered in terms of the Act, or when intended for export. per dosage unit, 0,5 milligrams or less of difenoxin, calculated as the base, and a quantity of atropine sulphate equal to at least 5 percent of such quantity of difenoxin, calculated as the ba se, as is present in the mixture. (S2) Diphenoxylate, except preparations containing not more than 2,5 milligrams of diphenoxylate, calculated as the base, and not less than 25 micrograms of atropine sulphate per dosage - see cathine} (-)-transdelta -9-tetrahydrocannabinol), except a. in raw plant material and processed products manufactured from such material, intended for industrial purposes and not for human or animal ingestion, containing 0,2 % percent or less of tetrahydrocannabinol; b. processed products made from cannabis containing 0,001 percent or less of tetrahydrocannabinol; or c. when raw plant material is cultivated, possessed and consumed by an adult, in private for personal consumption. Drotebanol. Ecgonin e, and the esters and derivatives thereof that are convertible to ecgonine and cocaine. Ephedra alkaloids (natural or synthetic), unless listed separately in the Schedules, DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 6 175 a. except products registered in terms of the Act, not intended for export, and being oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedra alkaloids per dose, with a maximum daily dose not exc eeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S2) b. except when intended for application to skin, eyes, ears and nares and containing 1 percent or less of ephedra alkaloids. (S1) Ephedrine, a. except products registered in terms of the Act, not intended for export, and being oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S2) b. except preparations and mixtures intended for application to the s kin, eyes, ears and nares and containing 1 percent or less of ephedrine. (S1) Ethylmethylthiambutene. Ethylmorphine, a. except oral solid preparations, in combination with one or more therapeutically active substances, and containing 20 milligrams or less of ethylmorphine (calculated as base) per dosage unit; (S2) and b. except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, and containing 20 milligrams or less of ethylmorphine (calculated as base) per 5 Etorphine and registered in terms of the Act and intended for the treatment of Attention Methyldihydromorphine. Schedule. Metopon. Moramide -intermediate. Morpheridine. Morphine, except preparations and mixtures of morphine containing 0,2 percent or less of morphine, Norpipanone. Opium and opiates and any sa lt, compound, derivative or preparation of opium or opiates, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or obtained independently by chemical synthesis, or by a combination of extraction and chem ical synthesis, except mixtures containing 0,2 percent or less of morphine, calculated as anhydrous morphine. (S2) Opium -poppy and poppy straw, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or wheth er obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis. Oxycodone (14 -hydroxydihydrocodeinone ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 6 178 a. except products registered in terms of the Act, not intended for export and oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does n ot exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children , limited to one pack per customer (S2) Pholcodine, except when prepared, mixed or compounded a. containing 20 milligrams or less of pholcodine (calculated as base) per dosage unit; or b. containing 20 milligrams or less of pholcodine (calculated as base) per 5 millilitre dosage unit in the case of liquid oral preparations and mixtures. (S2) Piminodine. Piritramide. Proheptazine. Properidine. Propiram. Pseudoephedrine, except contained in products registered in terms of the Act, and not intended for export, being oral preparations and mixtures containing not more than 60 milligrams or controlled -release oral preparations and mixtures containing not more than 120 milligrams of pseudoephedrine per dose, and not more than 240 milligrams per day, when in combinat ion with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, subject to a maximum pack size of 720 milligrams and limited to one pack per customer. (S2) Racemoramide. Racemorphan. Remifentanil. Secobarbital. Sufentanil. p-Synephrine, a. except preparations and mixtures registered in terms of the Act and intended for application to the skin, ears and nares containing 1 percent or less of p -synephrine and containing 0,2 percent or less for application to the eyes ; (S0) b. except oral preparations and mixtures registered in terms of the Act and intended for the symptomatic relief of nasal and sinus congestion, where the recommended daily dose for adults is 50 milligrams or less and for children 6 to 12 years is 25 mil ligrams or less, with a maximum pack size of 5 days; (S1) DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 6 179 c. except oral preparations and mixtures registered in terms of the Act and intended for the symptomatic relief of nasal and sinus congestion, where the recommended daily dose for adults is more than 5 0 milligrams and for children 6 to 12 years is more 1A: EMERGENCY CARE PROVIDER (PARAMEDIC) PARAMEDIC (National Diploma in Emergency Medical Care graduates only) registered with the Health Professions Council of South Africa PARAMEDIC (National Diploma in Emergency Medical Care graduates ) ANALGESICS Substance : Morphine s ulphate Indication : Opioid/Narcotic Route of Administration : Parenteral ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER) EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care) ANALGESICS Substance : Morphine s ulphate Indication : Opioid/Narcotic Route of Administration : Parenteral ANNEXURE 1E: EMERGENCY CARE TECHNICIAN EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa *ANALGESICS Substance : Morphine sulphate Indication : Opioid/Narcotic Route of Administration : Parenteral - END SCHEDULE 6 - DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 7 181 SCHEDULE 7 All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule): (i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation; (ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existenc e of isomers of such esters, or ethers is possible; (iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible; (iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible; (v) all preparations and mixtures of any of the above. (vi) all homologues of listed substances ( being any chemically related substances that incorporate a structural fragme nt into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules. (Trivial or unofficial names are marked *) and beta -aminoisopropylbenzene, except any compound structurally derived from either beta -aminopropylbenzene or beta -aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or by both such substitution an d such ring closure); and presented as: a. preparations and mixtures when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and b. appliances for inhalation in which the substance is absorbed onto solid material; (S1) c. use. (S6) Catha edulis (\"khat\"), the whole plant or any Cathinone (( -) -(S)-2-aminopropiophenone). CUMYL -4CN-8INACA Dexamfetamine (Dexamphetamine) except in medicines registered in terms of the Act and intended for the treatment of Attention -Deficit -methylfentanyl; (ii) alpha medicines registered in terms of the Act and intended for the treatment of Attention -Deficit Hyperactivity DocuSign Envelope ID: 98C48B9F-89C1-45BC-912C-507316ADF8D7Schedule 8 187 SCHEDULE 8 All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule): (i) the isomers of such substances, where the ex istence of such isomers is possible within the chemical designation; (ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of such isomers of esters and ethers is possible; (iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible; (iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible; (v) all preparations and mixtures of any of the above. Amfetamine ( Amphetamine ) and its salts; preparations thereof. (S7) "}